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ABSTRACT 
Megakaryocyte specification is the process by which discrete hematopoietic 
subpopulations undergo lineage commitment towards the myeloid compartment, 
finally specifying as a megakaryocyte erythroid progenitor (MEP) by way of 
thrombopoietin (TPO) and erythropoietin (EPO) signaling, before becoming a 
megakaryocyte lineage restricted progenitor that will progressively increase 
cellular ploidy and compartmentalize its cytoplasm in preparation for platelet 
production. With the advent of induced pluripotent stem cells (iPSCs), a cell type 
that is experimentally manipulated to function as embryonically derived 
pluripotent cells, there now exists the ability to analyze signal transduction 
throughout discrete phases of hematopoiesis, megakaryocyte lineage cell fate, 
and platelet production. Recent studies have implicated the aryl hydrocarbon 
receptor (AHR) as a transcription factor that plays a critical role in multiple 
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aspects of hematopoiesis. These results inspired the hypothesis that AHR 
signaling may be functionally relevant in the context of megakaryopoiesis. To test 
this hypothesis, an iPSC directed differentiation strategy was established in order 
to create a platform upon which to experimentally manipulate AHR signaling 
throughout megakaryocyte specification. The results demonstrate: 1) iPSC 
derived hematopoietic progenitor cells (HPCs) undergo exponential expansion 
upon AHR agonism; 2) AHR antagonism allows for megakaryocyte lineage bias; 
3) Optimization of directed-differentiation allows for the examination of AHR 
signaling in megakaryocyte lineage-restricted cells; 4) AHR signaling suppresses 
the expression of MPL, the gene that encodes the thrombopoietin receptor (C-
MPL) in iPSC derived megakaryocyte lineage committed cells; 5) AHR activation 
concomitantly suppresses cell surface expression of C-MPL, which may alter the 
sensitivity of HPCs to TPO signaling; 6) Multiple gene targets are modulated by 
AHR activation within megakaryocyte lineage cells, providing evidence of a 
transcriptional program downstream of AHR signaling that preferentially 
suppresses megakaryocyte specification; 7) A reporter iPSC line of AHR activity 
provides evidence of endogenous AHR signaling throughout megakaryocyte 
specification and shows a sharp decline in AHR activity upon megakaryocyte 
lineage commitment; 8) In a mouse model of megakaryocyte lineage specific 
AHR knockout, platelet counts are significantly reduced. These data suggest that 
the AHR plays a significant role in megakaryocyte specification by modulating the 
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expression of multiple lineage specific gene targets, including MPL, the 
thrombopoietin receptor.  
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INTRODUCTION 
Hematopoiesis: from mesoderm to blood 
The megakaryocyte is a unique, bone marrow resident blood cell that is 
responsible for producing platelets (Machlus and Italiano, 2013). Megakaryocytes 
are a part of the myeloid lineage of hematopoiesis (Machlus and Italiano, 2013) 
that includes other cell types (eosinophils, basophils, neutrophils, monocytes, 
and erythroid cells) that are proposed to specify downstream of the common 
myeloid progenitor (CMP) (Dzierzak and Speck, 2008). CMPs are differentiated 
into a bipotent progenitor of the megakaryocyte and erythroid lineages by way of 
thrombopoietin (TPO) and erythropoietin (EPO) signaling, before becoming a 
megakaryocyte lineage-restricted cell that will progressively increase cellular 
ploidy and compartmentalize its cytoplasm in preparation for platelet production 
(Akashi et al., 2000, Debili et al. 1996, Manz et al., 2002, Nakorn, Miyamoto, and 
Weissman, 2003, Pronk et al. 2016). 
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In order to fully appreciate the cytokines, growth factors, downstream 
signaling pathways, and spatial and temporal niche dynamics involved in the 
production of the megakaryocyte, developmental ontogeny, beginning with the 
pluripotent stem cell (PSC), must be fully realized. The crux of the work herein 
depends on recapitulating this process in an in vitro context, and the promise of 
working with induced pluripotent stem cells (iPSCs) hinges on painstaking efforts 
to faithfully reproduce megakaryopoiesis. Having the ability to differentiate 
megakaryocytes from an iPSC source requires a full understanding of primordial 
development, starting with the emergence of hemogenic endothelium, a subset 
of mesoderm with endothelial and hematopoietic lineage fate potential (Jaffredo 
Figure 1.1: Hematopoietic Ontogeny Megakaryocytes make up just one of eight distinct hematopoietic lineages, 
compartmentalized as coming from a myeloid or lymphoid progenitor. Downstream of the Common Myeloid Progenitor (CMP) 
is the Megakaryocyte Erythroid Progenitor (MEP), a bipotent progenitor of the megakaryocyte and erythroid lineages. Adapted 
from http://students.uccaribe.net/forms/topic/hematopoiesis-histology-image 
  
3 
et al., 2005), and culminating in the production of hematopoietic progenitor cells 
with the ability to differentiate towards the megakaryocyte compartment.  
Hematopoiesis by way of hemogenic endothelium 
 Hematopoietic cells are derived from a distinct population of mesodermal 
origin known as hematopoietic clusters (Dzierzak and Speck, 2008). Once 
termed “hemangioblasts”, they were first postulated to exist because of the 
observed proximity within the early chick embryo of endothelial cells and red 
blood cells that are now known to be a part of the “primitive wave” of 
hematopoiesis (Jaffredo et al., 2005, Murray, 1932). Further studies 
substantiated this observation, demonstrating that brachyury and fetal liver 
kinase 1 (FLK1) dual positive cells within the primitive streak of the mouse 
conceptus (Huber et al., 2004) migrate to the yolk sac and become bipotent 
progenitors of endothelial and hematopoietic lineages (Ferkowicz and Yoder, 
2005, Ueno and Weissman, 2006). These cells were once thought to become the 
hematopoietic stem cells (HSCs) that are resident to the fetal liver in later stages 
of embryogenesis, but it is now known that a separate source of mesoderm, from 
a more caudal region of the primitive streak, forms the lateral mesoderm from 
which hematopoietic cells that will populate the adult hematopoietic system arise 
(Kinder et al.,1999). Transplantation experiments in the mouse conceptus in 
early embryogenesis (from embryonic day 8 to 12) reveal that HSC reservoirs 
first appear in the aorta-gonad-mesonephros (AGM) region of the embryo at 
embryonic day 10.5 (Medvinsky and Dzierzak,1996), and these are widely 
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considered to be the cells that will ultimately populate within the fetal liver and 
expand to produce a large reservoir of HSCs (de Bruijn et al., 2000, Gekas et al., 
2005, Muller et al.,1994). These HSCs in particular express surface markers 
consistent with both hematopoietic and endothelial cell fate, suggesting that they 
too arise from an hemangioblast-like cell, but these cells are more accurately 
described as “hemogenic endothelium” in this later stage of maturation (Jaffredo 
et al., 2005) . As these cells have the capacity to specify to non-hematopoietic 
lineages, they are dependent upon signaling pathways that initiate a pro-
hematopoietic program that ultimately restricts their fate to become HSCs. 
Paracrine signaling between hemogenic endothelium and endodermal lineages 
are essential to initiate these cascades; namely, transforming growth factor beta 
(TGF-β), vascular endothelial growth factor (VEGF), and fibroblast growth factor 
(FGF) signaling pathways (Pardanaud and Dieterlen-Lievre, 1999). Indeed, these 
factors, along with bone morphogenetic protein 4 (BMP4), have previously been 
shown to induce hematopoietic specification (Kanatsu and Nishikawa, 1996) and 
increase HSCs in the AGM (Durand et al., 2007). These signaling pathways are 
commonly incorporated in directed differentiation protocols aimed at producing 
blood cells from PSCs in an in vitro context (Feng et al., 2014, Takayama and 
Eto, 2012). Established HSCs colonize distinct sites of hematopoiesis throughout 
embryogenesis, starting with the fetal liver, and culminating in the bone marrow, 
where hematopoietic ontogeny proceeds into birth and adulthood (Ciau-Uitz et 
al., 2014).  
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Hematopoietic Ontogeny 
The differentiation of HSCs into all eight blood cell lineages is a critical 
and tightly regulated physiological process (Orkin and Zon, 2008). Disruption of 
this regulation can have a profound downstream effect on multiple hematopoietic 
cell types, potentially leading to a myriad of blood cell disorders ranging from 
leukemia to stem cell exhaustion (Jude et al., 2007, Singh et al., 2011). However, 
definition of the molecular mechanisms that control specification of primary 
human blood cells has been hampered by the lack of a model system in which 
sufficient numbers of stem or progenitor cells can be grown and the absence of 
practical and efficient techniques for directing differentiation of hematologic 
progenitors into end stage cells. Several teams have published proof-of-principle 
examples of the derivation of megakaryocyte (Choi et al., 2009, Niwa et al., 
2009, Takayama et al., 2008) and erythroid-lineage cells (Choi et al., 2009, Ma et 
al., 2008, Niwa et al. 2009) from embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPSC). However, development of a model system which 
results in robust expansion of these cell populations or their immediate 
precursors and with which molecular signals driving cell differentiation can readily 
be studied has been problematic. To this end, we will describe in this thesis the 
derivation of iPSC lines created by the reprogramming of somatic cells with a 
lentiviral vector (hSTEMCCA) (Sommer et al., 2009, Sommer et al., 2012) that 
encodes the four transcription factors originally described as part of the discovery 
of the iPSC (Takahashi et al., 2007). We will then characterize resultant 
  
6 
hematopoietic cells with characteristics that mimic that of a bipotent progenitor of 
erythroid and megakaryocyte cell fate, the megakaryocyte erythroid progenitor 
(MEP) (Klimchenko et al., 2009).   
The putative megakaryocyte erythroid progenitor (MEP) 
Megakaryocytes (Mks) populate 0.1% of the nucleated bone marrow 
cellular compartment while producing roughly 1011 platelets per day in the adult 
human (Machlus and Italiano, 2013) . Hematopoietic cells specify to Mks through 
various stages of lineage commitment. First, the HSC specifies to the myeloid 
lineage through the common myeloid progenitor (CMP) and further differentiates 
into the megakaryocyte erythroid progenitor (MEP), a bipotent precursor of the 
Mk and erythroid lineages (Klimchenko et al., 2009). This cell was first 
discovered from subpopulations of CD34+ human bone marrow progenitors 
which were cultured in methylcellulose and found to produce a hematopoietic 
colony with erythroid cells in high abundance, surrounded exclusively by a small 
number of Mk lineage cells (Debili et al., 1996). This colony was termed a burst 
forming unit of the erythroid and Mk lineages (BFU-E/MK). Subsequent inquiries 
into this discrete cell type revealed a murine equivalent, first discovered in mice 
recovering from phenylhydrazine (PHZ)-induced hemolytic anemia, that led to the 
hypothesis that this cell type expands in response to acute stress in order to 
maintain erythroid and Mk homeostasis (Vannucchi et al., 2000). Parallel to this 
work, a comprehensive flow cytometry analysis found that c-kit+ murine 
hematopoietic progenitors from adult bone marrow contained an FcγRlo CD34- 
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cell fraction that exclusively produces colony forming unit-megakaryocyte (CFU-
Meg), burst forming unit-erythroid (BFU-E) or colony forming unit-megakaryocyte 
and erythroid (CFU-MegE) colonies, thus further characterizing the murine MEP 
(Akashi et al., 2000). Further work found that murine MEPs have high levels of 
Endoglin and CD150 surface expression (Pronk et al., 2007). Thus, this cell type 
has been successfully characterized in both mouse and human contexts. 
However, given new insight from mouse studies that have identified a platelet-
biased HSC (ref) as well as a unipotent megakaryocyte differentiation pathway 
(ref), which is unlikely to procede through a MEP intermediary, further work must 
be done to extend these findings to the human MEP, including a description of 
megakaryocyte homeostasis that will properly examine alternative pathways of 
hematopoietic ontogeny that have recently been proposed (Figure 1.2). 
Throughout this thesis, the term MEP will be used when describing work 
performed by outside investigators to describe cells from primary sources with 
restricted potential to the megakaryocyte and erythroid lineages; hematopoietic 
progenitor cell, or HPC, will be the moniker for our iPSC derived, MEP-like cells 
that are verified to have the capacity to differentiate to both the megakaryocyte 
and erythroid lineages but that have not been definitively shown to be unable to 
specify to other hematopoietic lineages.  
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Hematopoietic Stem Cells and Megakaryopoiesis 
As efforts mount to optimize megakaryopoiesis ex vivo, similarities in the 
mechanisms of HSC and Mk maintenance and expansion are of particular 
interest. Thrombopoietin (TPO), the major regulating cytokine of 
megakaryopoieisis, was first implicated in HSC homeostasis through studies of 
knockout mice for the TPO receptor (C-MPL) that identified deficiencies in the 
capacity of mpl-/- bone marrow to achieve long term hematopoietic reconstitution 
in irradiated recipients (Kimura et al., 1998). Further work proved that TPO/MPL 
signaling was crucial for the maintenance and expansion of quiescent long term-
HSCs (Qian et al., 2007). The field continues to expand upon these concepts, 
Figure 1.2: Alternative Pathways of Hematopoiesis A) The classical model of hematopoiesis, where each discrete progenitor is 
required for downstream specification to the megakaryocyte and erythroid lineages. B) A new model based upon findings that there 
may be a lympho-myeloid progenitor that can give rise to granulocyte lineage cells. C) A finalized version of hematopoietic ontogeny 
based upon multiple separate findings that show plasticity between the myeloid and lymphoid compartments as well as direct 
pathways to the megakaryocyte lineage that do not require normal myelopoiesis. Adapted from Woolthuis and Park, 2016.  
  
9 
providing evidence that megakaryocytes directly regulate HSC homeostasis and 
challenging what is known about hematopoietic ontogeny. Indeed, a subset of 
HSCs are now known to express the gene for von Willebrand’s factor (Vwf), a 
platelet-associated peptide once thought to be restricted to the Mk lineage. 
These cells produce greater transcript levels of mpl, and are primed for Mk 
lineage commitment (Sanjuan-Pla et al., 2013). This population is actively 
regulated by TPO and may precede all other HSC subsets, a finding that 
provides greater insight into the role of megakaryocyte-associated cytokines and 
HSC maintenance. Additionally, recent studies show that transplanted HSCs 
preferentially home to adjacent megakaryocytes within the endosteal bone 
marrow niche, where TPO promotes niche expansion (Olson et al., 2013), and 
mature megakaryocytes release cytokines to promote HSC proliferation 
(Heazlewood et al., 2013). Evidence now exists of a myeloid restricted progenitor 
that may be a direct descendant of the HSC, completely bypassing the 
multipotent progenitors thought to be a crucial intermediary of normal 
hematopoiesis (Yamamoto et al., 2013). This population may descend from 
CD41+ HSCs, recently discovered to be more quiescent and less proliferative 
than once thought (Gekas and Graf, 2013). These discoveries are part of a 
growing inquisition of hematopoietic hierarchy, and they reveal that progenitors 
are significantly plastic with respect to lineage commitment (Gorgens et al., 
2013). Thus, the Mk-lineage and its associated cytokines may be the primary 
regulator of the HSC, and platelet-biased HSCs and myeloid progenitors may 
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confer a rapid proliferative response for platelet reconstitution following acute 
stress.   
Megakaryocyte development and platelet production 
In the megakaryocyte lineage, TPO signaling activates the JAK2/STAT3 
pathway to produce transcriptional changes that promote Mk specification 
(Drachman, Rojnuckarin, and Kaushansky, 1999). Immature Mks undergo 
endoreplication in a largely TPO-driven process that results in large, 
multinucleate cells with the potential to reach upwards of 128N (Machlus and 
Italiano, 2013). These cells concomitantly form granular cytoskeletal 
compartments that extend into the bloodstream upon Mk homing to bone marrow 
sinusoidal endothelium (Gorgens et al., 2013).  Dense granules and alpha 
granules, two types of platelet specific organelles that secrete growth factors and 
coagulation stimulators, travel along microtubule bundles to the distal tip of the 
“proplatelet”, where shear forces generated from the bloodstream dissociate the 
proplatelet and form the enucleate, circulating platelet (Machlus and Italiano, 
2013). This process has been described by multiple groups (Kaushansky, 2015) 
but the mechanisms that are critical to megakaryocyte maturation and platelet 
production are not yet fully characterized. Thus, the development of an in vitro 
platform that captures discrete events throughout megakaryopoieis is critical to 
advance this field.  
The clinical potential for iPSC-derived megakaryocytes and platelets 
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Thrombocytopenia, defined as a significantly low platelet count, is a 
pervasive clinical outcome that is symptomatic of a broad range of disorders. 
Platelet counts can become inappropriately low as a result of decreased platelet 
production or increased clearance, and thrombocytopenic disorders are 
categorized based upon this distinction (Smock and Perkins, 2014). 
Thrombocytopenic patients typically present with an increased propensity for 
bruising, with some suffering from dangerous bleeding episodes for which 
platelet transfusion is the preferred course of treatment. Despite this prevalent 
clinical need, drug treatment options are confined to the use of thrombopoietin 
receptor agonists (TRAs), compounds that have proven efficacious in some 
patients but carry the risk of inducing thrombotic episodes in others (Afdhal et al., 
2012). Platelet donations are an invaluable therapeutic option but are often in 
scarce supply and can elicit an anaphylactic response (Kiefel, 2008). It is for this 
reason that multiple laboratories seek to develop scalable protocols for the in 
vitro derivation of transplantable platelets from iPSCs (Garber, 2013). As iPSCs 
are derived from primary human tissue, in vitro derived platelets can be created 
from patient-specific iPSC lines that allow for syngeneic transfusion and, 
theoretically, prevention of a refractory immune response. These iPSCs not only 
have the potential to be patient-specific but gene edited and corrected in order to 
ameliorate disease (Hirata et al., 2013, Sullivan et al., 2014). To this end, 
conditions that promote megakaryocyte differentiation in vivo must be emulated 
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in iPSC-directed differentiation strategies in order to produce the sheer quantity 
of in vitro derived platelets necessary for therapeutic application. 
Immortalization of megakaryocyte progenitors 
Early attempts at optimizing stem cell derived megakaryocyte production 
involved embryonic stem cell (ESC)-derived megakaryocytes that propagated 
from “ES-sacs”, consisting of hematopoietic progenitors surrounded by 
hemogenic endothelium (Takayama et al., 2008). Recently, the same group (Eto 
and colleagues) optimized this strategy through forced expression of 
immortalization factors, effectively creating immortalized megakaryocyte 
progenitors (imMKCLs) from ESCs and iPSCs (Nakamura et al., 2014). Drawing 
upon their previous report of the role of c-MYC in megakaryopoiesis (Takayama 
et al., 2010), they transduced megakaryocyte progenitors with C-MYC to promote 
progenitor expansion, along with BMI1 to suppress senescence and BCL-XL to 
prevent apoptosis. ImMKCLs were readily expanded and cryopreserved with the 
ability to thaw for later use, an unprecedented innovation that may be of vital 
importance for translating this technology to the clinic. Importantly, inducible 
suppression of these three immortalization factors promoted terminal Mk 
differentiation and the production of agonist-responsive platelets (Nakamura et 
al., 2014).  
Emulation of bone marrow microenvironments 
With the growing emphasis on recapitulating the bone marrow niche 
during in vitro megakaryopoiesis, technical advances have been made to allow 
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for manipulation of multiple parameters (i.e. pH, pO2, and shear stress) that may 
provide optimal conditions for high yields of functional, inactivated platelets. 
Using human CD34+ peripheral blood cells as starting material, an elegant 
optimization strategy was published that screened for various cytokine cocktails 
and other complex culture conditions (Panuganti et al., 2013). In this study, it was 
found that a three phase culture system that steadily increases pH and pO2 is 
optimal for generating polyploid Mks and promoting platelet generation 
(Panuganti et al., 2013). Additionally, the group that developed the 
aforementioned imMKCLs posited that Mks derived from immortalized 
progenitors could be incorporated into a dynamic culture system that they had 
reported on earlier in the year (Nakagawa et al., 2013). A bioreactor system was 
developed that utilizes microfluidic flow, a technique precipitated by studies 
showing shear stress as an inducer of platelet production in vivo (Junt et al., 
2007). A microfluidic chamber was generated by way of a wax mold made 
porous through salt leaching. This chamber was designed to mimic the porous 
bone marrow microvasculature to which megakaryocytes home and extend 
proplatelets into circulation. As such, the authors seeded the porous structure 
with human umbilical cord vascular endothelial cells (HUVECs) and introduced 
bidirectional flow. The resultant platelet yield was significantly greater than that of 
static culture and the derived platelets were agonist responsive as assessed by 
integrin activation. Other groups have since contributed novel bioreactor systems 
as well, including a recent effort to recapitulate physiologic shear forces that act 
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upon the megakaryocyte in vivo (Thon et al., 2014). Taken together, current 
optimization strategies for high yield platelet production incorporate immortalized 
progenitors and recapitulate the bone marrow microenvironment to mimic in vivo 
thrombopoiesis.   
Clinical barriers for stem cell-derived platelets 
With the unprecedented expansion of pluripotent stem cell derived 
platelets recently reported in the literature (Nakagawa et al., 2013, Nakamura et 
al., 2014, Pick et al., 2013), it is seemingly a foregone conclusion that these cells 
will one day be of great clinical importance. Presently, there remain significant 
issues throughout the field that must be addressed before these cells can be 
relied upon as a safe alternative to existing treatment. Though this notion has 
become controversial in recent years, it is typically accepted that adult Mk ploidy 
is correlated with terminal maturation and efficient platelet production. While 
human megakaryocytes can generate nuclear DNA content of 128N (Zimmet and 
Ravid, 2000), ex vivo differentiation strategies of ESCs and iPSCs cannot reliably 
produce cells of greater than 32N (Lu et al., 2011). In order to make a platelet 
yield that can be scaled for clinical transfusion, platelet number per 
megakaryocyte must be demonstrably greater than what can currently be 
achieved, and doubt still exists as to whether the inability to produce high ploidy 
Mks ex vivo contributes to this deficit. While it is important that derived platelets 
display a proper morphology and in vitro functionality, these cells must also avoid 
inappropriate activation prior to transplantation, a problem that persists with 
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many differentiation strategies. Platelets are known to be highly susceptible to ex 
vivo activation from improperly buffered media, harvesting methods (i.e. 
centrifugation), and protease activity (Metcalfe et al., 1997). Platelet activation 
that results from long term storage can lead to decreased recovery and viability 
in transfused recipients (Rinder et al., 1991). Thus, stem cell differentiated 
platelets must be kept in an inactivated state in order to be clinically efficacious. 
Deficiencies in Mk ploidy and platelet activation must be addressed before 
derived platelets can be used as cellular therapy. 
Stem cell platforms provide the experimental infrastructure to discover 
novel signaling pathways of megakaryopoiesis 
Studies that utilize stem cell differentiation to the Mk lineage continue to 
reveal the complexity of megakaryocytes by implicating various signaling 
pathways in their differentiation and function. Multiple studies have uncovered 
dysregulated signaling that may reveal novel regulators of megakaryopoiesis. 
These factors include, but are not limited to, platelet endothelial aggregation 
receptor-1 (PEAR-1), a stimulator of PI3K/PTEN signaling (Kauskot et al., 2013), 
and RAD001, an mTOR inhibitor currently used as a chemotherapeutic and 
immunosuppressant (Su et al., 2013).  Wnt3a has also been implicated as a 
repressor of human Mk progenitor expansion in an in vitro iPSC derivation 
system that causes robust production of CD41/CD235 dual positive progenitors 
(Paluru et al., 2014). This finding is in direct conflict with studies of Wnt3a 
signaling in the murine system (Nostro et al., 2008), thus highlighting the 
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importance of incorporating human models of hematopoietic differentiation. 
Additionally, the role of RUNX1 as a master regulator of megakaryocyte fate has 
been greatly expanded by way of stem cell modeling. RUNX1 has previously 
been shown to directly activate megakaryocyte-associated genes including 
ITGA2B, GP1BA, and C-MPL (Elagib et al., 2003, Satoh et al., 2008). Currently, 
mutations in RUNX1 have been implicated in the etiology of Familial Platelet 
Disorder (FPD) and shown to abrogate platelet factor 4 (PF4) expression in an 
embryonic stem cell differentiation system, providing a plausible mechanism for 
the FPD phenotype (Okada et al., 2013). These studies highlight the importance 
of RUNX1 in the active differentiation of megakaryocytes. Taken together, the 
highlighted works demonstrate that stem cell platforms are ideal for uncovering 
multiple signaling pathways that impact normal and abnormal megakaryopoiesis.  
The work herein explores the role of a ligand activated transcription factor 
known as the aryl hydrocarbon receptor (AHR) in megakaryocyte biology. This 
receptor has been shown to have regulatory cross-talk with multiple other 
signaling cascades (Goel and Mercurio, 2013, Pickup, Novitskiy, and Moses, 
2013) and has recently been shown to regulate the transcription of RUNX1 
(Stanford, 2015). This pathway will be explored in the context of an iPSC directed 
differentiation strategy to the Mk and erythroid lineages using small molecule 
AHR modulators and, importantly, a CRISPR/CAS9 strategy that incorporates a 
reporter construct downstream of the endogenous locus of an AHR target gene 
(Bock and Kohle, 2009). Clustered regularly interspersed short palindromic 
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repeats (CRISPRs) have been identified as an element of bacterial adaptive 
immunity by which foreign DNA of invading species is incorporated into the host 
genome and subsequently used as a template upon which CRISPR associated 
(CAS) endonucleases bind and digest newly infected DNA (Wiedenheft et al, 
2012). Multiple groups have adapted this technology to mammalian systems to 
improve upon pre-existing methodologies and have confirmed that this tool is 
highly accessible and amenable to targeted genome editing (Seah et al, 2015). 
Despite the promise of this technology, there remains a paucity of studies that 
examine the AHR within the context of iPSC directed differentiation (Hu et al, 
2013, Smith and Rozelle et al., 2013) or incorporate CRISPR/CAS9 to employ 
genetic manipulation of AHR signaling (Aluru et al., 2015). Therefore, exploration 
of the AHR in this work will utilize novel technologies in order to reveal its role in 
hematopoietic differentiation to the megakaryocyte lineage. 
The aryl hydrocarbon receptor (AHR)  
The AHR is a member of the evolutionarily conserved Per/ARNT/SIM 
(PAS) family of basic helix-loop-helix (bHLH) transcription factors (Hahn, 2002). It 
is the only PAS family member known to be activated by endogenous or 
exogenous ligands. In the absence of ligand, the AHR is bound by the chaperone 
protein HSP90 along with p23 and AIP (Hollingshead, Petrulis, and Perdew, 
2004). Upon ligand binding, the AHR undergoes a conformational change that 
exposes its nuclear localization signal (NLS), causing it to lose affinity to the 
chaperone complex and enter the nucleus (Lees and Whitelaw, 1999). Once in 
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the nucleus, the AHR dimerizes to the AHR nuclear translocator (ARNT) that 
directly binds to genomic cis targets known as AHR response elements (AHREs) 
with the consensus sequence 5’-TNGCGTC-3’ that is localized to the promoters 
of AHR gene targets (Sun et al., 2004). These genes include members of the 
Cytochrome P450 family of detoxifying phase I enzymes, CYP1A1 and CYP1B1 
(Nebert et al., 2000), as well as the AHR repressor (AHRR), a competitive 
inhibitor of ARNT binding that ultimately negatively regulates AHR activity 
(Mimura et al., 1999). This, in conjunction with exposure of the AHR nuclear 
export sequence (NES) (Ikuta et al., 1998), terminates the signal, leading to the 
AHR being shuttled to the cytoplasm and degraded by the proteasome 
(Davarinos and Pollenz, 1999). (Figure 1.3) 
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Historically, the AHR was studied in the context of its activation by a 
variety of ubiquitous environmental pollutants including dioxins, polychlorinated 
biphenyls (PCBs), and polycyclic aromatic hydrocarbons (PAHs) (Beischlag et 
al., 2008, Spink et al., 2002). However, the AHR field has recently undergone a 
major paradigm shift following the demonstration that the AHR plays important 
physiological roles in the absence of environmental ligands. Multiple studies 
suggest the AHR pathway is important in the development and function of the 
Figure 1.3: AHR Signalling Pathway Ligands canonically associated with AHR activation (TCDD, PCB, etc) enter the cell and bind the AHR, leading to translocation to the 
nucleus. The AHR dimerizes with the AHR nuclear translocator (ARNT) and causes a transcriptional change. Among the targets of this pathway are the cytochrome P450 
detoxifying enzymes CYP1A1 and CYP1B1 as well as the AHR repressor (AHRR) which leads to competitive inhibition of AHR:ARNT dimerization and a resultant supression 
of the AHR pathway. Adapted from Bersten et al, 2013) 
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cardiovascular system in the AHR -/- mouse (Lahvis et al., 2000, Nan Zhang, 
2011, Thackaberry et al., 2002, Vasquez et al., 2003), without the presence of an 
experimental ligand. Indeed, it is this same model organism that displays varied 
and diverse developmental phenotypes including, but not limited to, reduced liver 
size, increased portal tract fibrosis (Fernandez-Salguero et al., 1995), decreased 
fertility (Abbott et al., 1999, Baba et al., 2005), a suspected resistance to 
neurotoxicity (Garcia-Lara et al., 2015) and an impairment in the lymphocyte 
compartment (Esser, 2009). Observed roles of the AHR in immunity and 
inflammation (Cella and Colonna, 2015) as well as the discovery of novel 
endogenous AHR agonists (Denison and Nagy, 2003), add to the overwhelming 
evidence that AHR signaling is endogenously regulated and crucially important 
throughout development. Compounded with evidence of regulatory crosstalk with 
VEGF and TGF-β pathways (Goel and Mercurio, 2013, Pickup, Novitskiy, and 
Moses, 2013), these studies seem to suggest that multiple roles of AHR signaling 
have yet to be discovered. Currently, the reigning hypothesis is that the 
endogenous physiological roles of the AHR reflect the presence of previously 
unknown endogenous ligands (Nguyen and Bradfield, 2007). These include, but 
are not limited to, tryptophan derivatives such as FICZ (Nuti et al., 2014, Wei et 
al., 1998) and indoxyl sulfate (Schroeder et al., 2010) to bilirubin, a natural 
product of heme catabolism (Phelan et al., 1998, Togawa, Shinkai, and Mizutani, 
2008) and the arachadonic acid metabolites prostaglandin G (Seidel et al., 2001) 
and lipoxin A4 (Machado et al., 2006). As this field expands and more small 
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molecule compounds are identified as a part of AHR regulation, the implication 
that AHR signaling is regulated by endogenous ligands will be further 
substantiated. 
Hematopoiesis and the AHR  
Recent breakthrough studies suggest that the AHR plays a critical role in 
HSC growth and differentiation (Boitano et al., 2010). Murine and human HSCs 
express the AHR (Singh, Casado, et al., 2009, Singh et al., 2011, Singh, Wyman, 
et al., 2009), with in vivo AHR modulation resulting in disruption of HSC growth, 
senescence, and migration (Boitano et al., 2010, Casado, Singh, and Gasiewicz, 
2010, Casado, Singh, and Gasiewicz, 2011, Gasiewicz, Singh, and Bennett, 
2014). AHR-/- mice exhibit an increased number of bone marrow HSCs (Singh et 
al., 2011) and a commensurate propensity to develop lymphomas (Sherr and 
Monti, 2013). These insights led to the hypothesis that the AHR, activated by 
endogenous ligands, regulates stem cell growth and/or differentiation (Liu, 
Santostefano, and Safe, 1994). Despite these early results, little is known about 
the effects of AHR modulation on the development of megakaryocyte (Mk) or 
erythroid-lineage cells from bipotential progenitors. Involvement of the AHR in 
this process is suggested by decreased numbers of erythrocytes and platelets in 
young AHR-/- mice and the skewing of the blood cell repertoire towards myeloid 
and B lineage cells as AHR-/- mice age (Beischlag et al., 2008, Spink et al., 
2003, Spink et al., 2002). Specifically with regard to hematopoietic 
subpopulations, the AHR regulates development of Th17 cells, regulatory T cell 
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subsets, and gut-associated T cells (Abdelrahim, Smith, and Safe, 2003, Afdhal 
et al., 2012, Boitano et al., 2010, Hahn, 2002, Lindsey et al., 2014, Miller, 
Holloway, and Foster, 2005, Smock and Perkins, 2014). Taken together, there 
seem to be multiple roles associated with AHR signaling in various cellular 
contexts throughout distinct lineages of hematopoietic cells. 
AHR function in megakaryocyte specification and platelet release 
 The AHR knockout mouse has provided researchers with multiple insights 
into the proposed endogenous roles of AHR signaling. As a consequence of a 
whole body knockout of AHR pathway activation (AHR-/-), this mouse displays a 
wide array of phenotypes that are specific to the megakaryocyte and the platelet 
(Lindsey et al., 2014, Lindsey and Papoutsakis, 2011). Notably, these include an 
observed lack of high ploidy megakaryocytes (Lindsey and Papoutsakis, 2011), a 
15% decrease of platelets in AHR-/- mice, and an impairment of collagen-
dependent platelet activation (Lindsey et al., 2014). A relative lack of collagen 
responsiveness in these platelets was attributed to the concomitant loss of the 
VAV family of guanine nucleotide exchange factors (GEFs), particularly VAV1 
and VAV3 (Lindsey et al., 2014). These factors are required for downstream 
phosphorylation of phospholipase C gamma (PLCγ) that results from collagen 
binding to its dedicated integrin receptor (GPVI) on the surface of platelets 
(Pearce et al., 2004). To address these findings, the work herein will incorporate 
a megakaryocyte lineage-restricted mouse model of AHR knockout (AHRfl/fl PF4-
Cre+) (Tiedt et al., 2007, Walisser et al., 2005). This mouse retains AHR 
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signaling throughout development, but is excised by Cre/LoxP technology once 
megakaryocyte lineage cells drive the expression of PF4. These cells initiate 
transgenic expression of cre recombinase, leading to the floxed exon 2 of the 
AHR to be excised and AHR expression to be knocked out. This lineage-
restricted knockout system provides a more defined picture of the consequences 
of a lack of the AHR pathway within megakaryocytes and platelets (Tiedt et al., 
2007, Walisser et al., 2005). 
Definition of Hypothesis and Experimental Aims 
 Here, we hypothesize that the AHR plays a significant role in 
megakaryocyte specification from dedicated hematopoietic progenitors. We 
speculate that the AHR transcriptionally regulates genes that are implicit in 
megakaryopoiesis. We have defined three major aims to elucidate the role of the 
AHR in both early megakaryocyte specification and late stage megakaryocyte 
maturation and platelet production. Our first aim is to develop a novel, human 
iPSC-based model of megakaryocyte development in order to capture 
hematopoietic ontogeny and experimentally manipulate AHR signaling. Our 
second aim is to explore the influence of the AHR in early megakaryocyte-
lineage specification by probing for megakaryocyte associated transcriptional 
targets and developing a temporal map of the AHR throughout our hematopoietic 
specification protocols. Our third aim is to identify the role of AHR signaling in 
late-stage megakaryopoiesis and platelet production by incorporating an in vivo 
model of megakaryocyte lineage-restricted AHR knockout. 
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AIM ONE 
Our first aim is to develop a novel, human iPSC-based model of 
megakaryocyte development. 
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AIM ONE METHODS  
Chemicals 
 DMSO, β-Napthoflavone (β-NF), and 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
(TCDD), were obtained from Sigma-Aldrich (St. Louis, MO). 6-Formylindolo(3,2-
b)carbazole (FICZ) was obtained from Santa Cruz Biotechnology (Dallas, TX). 
iPSC Derivation and Culture  
iPSC derivation was achieved using the hSTEMCCA lentiviral vector as 
previously described (Somers et al. 2010).  Peripheral Blood Mononuclear Cells 
(PBMCs) were used as source material for iPSC production. Samples were 
centrifuged at 37°C for 25 minutes at 1800 rcf and the resulting buffy coat was 
collected in a 15ml falcon tube. Cells were resuspended in 2 ml of expansion 
medium, consisting of QBSF-60 (Quality Biological 160-204-101), 50 ng/ml hSCF 
(R&D 255-SC-010), 10 ng/ml hIL-3 (R&D 203-IL-010), 2 U/ml hEPOgen 
(Amgen), 40 ng/ml hIGF-1 (R&D 291-GI-050), 50 µg/ml Ascorbic Acid (Sigma 
A4403), 100 µg/ml Primocin (Invivogen ant-pm-2) and 1 µM Dexamethasone 
(Sigma D4902).  After 8-9 days, polybrene was added to the media (5 µg/ml) and 
the hSTEMCCA lentivirus was added to the culture at an MOI ranging from 1 to 
10.  After 24 hours, the inoculated culture was spun at 2250 g for 90 minutes and 
the polybrene media was discarded.  The cells were then plated onto irradiated 
Mouse Embryonic Fibroblasts (iMEFs) and cultured for roughly 15 days in “iPSC 
media” that includes DMEM F12 (Invitrogen 11330057) 10 ng/ml bFGF (R&D 
233-FB-025) 1 ng/ml Rho Kinase Inhibitor (Cayman Chemical 10005583) 20% 
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Knock-out Replacement Serum (KOSR) (Invitrogen 10828028) and 100 µg/ml 
Primocin.  Clones were then picked and expanded for long-term culture.   
Directed Differentiation of iPSCs into Hematopoietic Cells  
iPSCs were plated onto matrigel coated 6-well plates in iPSC media 
conditioned on iMEFs for 24 hours and supplemented with 2 ng/ml Rho Kinase 
Inhibitor and 20 ng/ml bFGF.  After two days, iPSC media was replaced with 
media cocktails designed to initiate hematopoietic specification: D0-1 media: 
RPMI (Invitrogen A1049101) supplemented with 5ng/ml hBMP-4 (R&D 314-BP-
010), 50ng/ml hVEGF (R&D 293-VE-010), 25ng/ml hWnt3a (R&D 287-TC-500) 
and 10% KOSR; D2 media: RPMI supplemented with 5ng/ml hBMP-4, 50ng/ml 
hVEGF, 20ng/ml bFGF and 10% KOSR;  D3 media: StemPro 34 (Invitrogen 
10639011), 5ng/ml hBMP-4, 50ng/ml hVEGF, and 20ng/ml bFGF; D4-5 media: 
StemPro 34, 15ng/ml hVEGF, and 5ng/ml bFGF; D6 media: 74% IMDM 
(Invitrogen 12330061), 24% Hams F12 (Mediatech 10-080-CV), 1% B27 
supplement (Invitrogen 12587-010), 0.5% N2-supplement (Invitrogen 17502-
048), 0.5% BSA (Sigma A3059), 50ng/ml hVEGF, 100ng/ml bFGF, 100 ng/ml 
hSCF (R&D 255-SC-010), 25ng/ml hFlt3 Ligand (R&D 308-FKN-005);  D7 media: 
74% IMDM, 24% Hams F12, 1% B27 supplement, 0.5% N2-supplement, 0.5% 
BSA, 50ng/ml hVEGF, 100ng/ml bFGF, 100ng/ml hSCF, 25ng/ml hFlt3 Ligand, 
50ng/ml hTPO (Genentech G140BT), 10ng/ml IL-6 (R&D 206-IL-010), 0.5U/ml 
hEPOgen and 0.2 µM 6-formylindolo[3,2-b]carbazole (FICZ) (Santa Cruz 
SC300019).  After Day 7, 0.5ml of Day 7 media was added to the culture daily 
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without aspirating the media from the previous day.  All base media mixes 
included 2mM L-Glutamine (Invitrogen 25030081), 4x10^-4 M Monothioglycerol 
(Sigma M1753), 100 µg/ml Primocin, and 50ug/ml Ascorbic Acid.  Cells in 
suspension were collected and assayed at Days 10-15 or split for long-term 
culture.   
Megakaryocyte and erythroid lineage specification of MEPs  
Mk-lineage cells were generated from Day 15 MEPs by first washing the 
cells and placing them in Mk specification media containing IMDM, 0.5% BSA, 
10µg/ml NTPs and dNTPs (Invitrogen), 40µg/ml LDL (Sigma L8292), 200µg/ml 
human holo-transferrin (Sigma T0665), 10µg/ml human insulin (Sigma I3536), 
50µM 2-ME, and 100ng/ml human TPO. Mature megakaryocytes were grown on 
an OP9 stromal layer for 3 to 5 days to allow for terminal megakaryocyte 
differentiation and platelet production. 
Colony forming assays 
 Colony forming cell assays utilized unsorted D15 non-adherent cell 
populations in which 28,000 cells per assay were grown in methylcellulose with 
hematopoietic growth factors for 12 days. Colonies were scored using bright field 
microscopy.   
Lentiviral vector generation and application 
The AHR repressor was cloned into the pHAGE2 lentiviral Ef1α-
dsRed(NLS)-IRES-ZsGreen.  Primers were designed to amplify the f.heteroclitus 
AHRR coding region from an HPV422-based construct, with NotI / BamHI cut 
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sites incorporated at the 5’ and 3’ sites respectively. VSV-G pseudotyped 
lentivirus was packaged and concentrated as previously described. Cells were 
infected overnight and subsequent ZsGreen expression was monitored by 
fluorescence microscopy and flow cytometry as indicated in the text. 
Quantitative RT-PCR  
RNA was extracted using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions and DNase treated using the DNA-free kit (Ambion 
AM1906).  Reverse transcription into cDNA was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems 4368814).  
Quantitative (real time) PCR amplification of cDNA was performed using Taqman 
probes for CYP1B1 (Hs002382916_s1), HBA (Hs00361191_g1), HBB 
(Hs00758889_s1), HBG (Hs01629437_s1), PF4 (Hs00427220_g1), NF-E2 
(Hs00232351_m1) CD62P (Hs00927900_m1), GPIIb (Hs01116228_m1), and 
GPV (Hs03027242_s1) run on the Applied Biosystems StepOne machine.  
Relative gene expression was normalized to β-actin (Hs99999903_m1) or SYBR 
green primers specific to GAPDH (Forward: 5’-
GGAAATCCCATCACCATCTTCCAGG-3’; Reverse: 5’-
GCAAATGAGCCCCAGCCTTCTC-3’) as indicated. 
Flow Cytometry   
Roughly 10^5 cells were collected, spun, and re-suspended in 0.5% BSA 
in PBS.  Samples were incubated for 30 min at ambient temperature with human 
antibodies including CD41a-FITC (BD 555466), CD235-PE (BD 555570), and 
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CD42b-PE (BD 555473), washed and spun at 3300 rpm for 7 min, and re-
suspended in 0.5% BSA in PBS with 1 µg/ml Propidium Iodide.  Samples were 
run on a BD FACScalibur using Cellquest Pro software and analyzed via FloJo 
8.7.  For ploidy analysis, cells were treated with 1.5% NP-40 (Boston Bioproducts 
P-872) and 62.5 µg/ml Propidium Iodide in PBS immediately before FACScalibur 
interrogation.  For murine bone marrow, samples were first incubated for 5 min at 
ambient temperature with murine conjugated antibody CD16/32 (BD 553142) 
before a 30 min incubation with c-Kit-PE (BD 553355), CD41a-FITC (BD 
553848), Ter119-PE (BD 553673). For cell viability assays, 2-3 x 10^5 cells were 
collected and resuspended in 8.8 µg/ml Hoecsht 33342 in PBS supplemented 
with 5% FBS.  Samples were then incubated in the dark at 37°C for 15 min, 
washed, and re-suspended in 1 µg/ml Propidium Iodide in 5% FBS.  Samples 
were run on an LSR-II machine with FACSDiva software and analyzed via FloJo 
8.7.        
Statistical Analysis   
Results are presented as the mean ± the standard deviation of 
experiments performed in triplicate.  Statistical significance was confirmed using 
the Student’s t-test. 
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AIM ONE RESULTS 
The feeder-free, chemically defined production of HPCs from iPSCs 
produces populations of cells that express markers of both the 
megakaryocyte and erythroid lineages 
The clinical translation of iPSC-based technologies will require many 
modifications to improve the efficiency of generation and the safety profile of 
iPSC-derived cells. Using a novel, feeder cell-free, chemically-defined system for 
the production of hematopoietic progenitor cells from human iPSCs that is not 
beholden to the use of stromal cell lines or xenogeneic agents, our primary goal 
was the production of large numbers of clinically relevant, high purity 
hematopoietic cells. Our approach follows the roadmap provided by the 
developing embryo. Since ESCs and iPSCs resemble pluripotent, 
undifferentiated cells of the early blastocyst embryo, the signals active in the 
early embryo were harnessed to direct the differentiation of iPSCs in vitro. Due to 
the known variability in the formation of human embryoid bodies (Bratt-Leal, 
Carpenedo, and McDevitt, 2009), this protocol utilizes a 2D culture system 
optimized to produce hematopoietic progenitor cells within 10-15 days (Figure 1).  
In this system, differentiating iPSCs produce an endothelial-like adherent 
layer from which non-adherent hematopoietic cells emerge beginning at Day 7 
(Figure 1). Days 7-15 are characterized by the rapid outgrowth of non-adherent 
cells. As defined by immunophenotyping at Day 15, greater than 50% of these 
non-adherent cells co-express CD235-glycophorin A (erythroid lineage) and 
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CD41a (Mk lineage) suggesting that at least a portion of the hematopoietic 
progenitor cells (HPCs) generated were bipotential MEPs (Figure 2). When 
placed in colony forming assays, this total, unsorted population of cells produced 
roughly equal numbers of mixed, myeloid- and erythroid-lineage colonies, 
suggesting the presence of bipotential MEPs, as well as committed Mk- and 
erythroid-lineage cells (Figure 3).  In comparison to undifferentiated iPSCs, these 
cells also significantly upregulated globin genes characteristic of erythroid-
lineage cells as well as PF4, CD62P, and NFE2, genes characteristic of Mk-
lineage cells (Figure 4). The latter three factors are indicative of a megakaryocyte 
transcriptome but are in no way used to phenotype these cells as such, just to 
substantiate the immunophenotyping data herein. Note that the timeframe to 
generate what phenotypically appear to be MEPs is significantly shorter than that 
noted in previously described protocols (Gekas and Graf, 2010, Takayama et al., 
2008) and that no fractionation or further manipulation of the cells is required. 
These results are consistent with the presence of functionally bipotent MEPs. 
A crucial roadblock in the translation of iPSC technology is the ability to 
produce sufficient, clinically relevant quantities of cells. Even for basic research 
studies, the numbers and quality of hematopoietic cells that can be produced 
through the directed differentiation of iPSCs can be limiting (Chang, Bonig, and 
Papayannopoulou, 2011). With the outgrowth of HPCs by day 15 of culture, we 
were presented with the possibility that ongoing AHR activation could continue to 
drive progenitor expansion. Here, we demonstrate that the AHR agonist FICZ 
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has the ability to allow for the exponential expansion of iPSC-derived 
hematopoietic progenitor cells.  In comparison to untreated control samples, 
FICZ-treated HPCs demonstrate significantly less cell death as judged by 
propidium iodide and Hoecsht dye exclusion, as well as significantly more 
proliferation as judged by EdU (5-ethynyl-2’-deoxyuridine) incorporation (Figures 
5A-D). Furthermore, in contrast to untreated cells in which 500,000 HPCs yielded 
4 million cells (8 fold increase), FICZ-treated day 15 HPCs demonstrated 
logarithmic expansion such that FICZ treatment of 500,000 HPCs yielded 300 
million cells (600 fold increase) within 10 days (Figure 5E). 
AHR mediates the expansion and specification of hematopoietic 
progenitors 
The results presented above strongly suggest that AHR hyper-activation 
drives human HPC expansion. To further test this hypothesis, AHR expression 
and functionality in both undifferentiated iPSCs and differentiated HPCs were 
investigated. Little or no AHR receptor protein was detected in human iPSC by 
western blotting (Figure 6A). However, a significant increase in expression of the 
prototypic AHR target gene, CYP1B1 was seen by qPCR 72 hrs after treatment 
with 0.2µM FICZ suggesting that iPSCs express AHR but at levels below those 
detectable in western blots (Figure 6B). Similarly, AHR protein was not detected 
in day 15 HPCs. However, treatment of day 15 HPCs with FICZ significantly 
induced CYP1B1 expression (Figure 6B). Similar data were obtained with two 
other AHR agonists, β-naphthoflavone (BNF) and the prototypic environmental 
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AHR ligand, 2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD) (Figure 7). In contrast to 
iPSCs or day 15 HPCs, AHR was robustly expressed in day 30 and day 60 HPCs 
(Figure 6A).  
AHR repression promotes megakaryocyte specification  
As the default pathway in our system seemed to allow for the specification 
and maturation of iPSC-derived HPCs into the red cell lineage under chronic 
AHR agonism, we hypothesized that AHR down-regulation in these long-term 
cultures might allow for the emergence of an alternative lineage, 
megakaryocytes. To test this hypothesis, we constructed and utilized a lentiviral 
vector that encodes an AHR repressor element (AHRR) along with a ZsGreen 
reporter (Figure 8A). This AHRR element potently and specifically inhibits either 
baseline or AHR agonist-induced AHR transcriptional activity (Evans et al., 2008, 
Hahn, Allan, and Sherr, 2009). In contrast to cells transduced with a control 
ZsGreen reporter, cells infected with the AHRR-ZsGreen lentivirus and cultured 
for 5 days produce a significantly higher number of large, CD41+ Mk-lineage 
cells (Figure 8B and C). Interestingly, while the AHRR-transduced populations 
were capable of producing Mk-lineage cells, they also contained fewer CD235+ 
cells, suggesting that AHR antagonism initiates a transcriptional switch from 
erythroid to megakaryocyte lineage specification (Figure 8C).   
To further study the Mk-lineage cells produced via AHR antagonism, a 
discontinuous BSA gradient (0, 1.5, 3%) was used to isolate mature Mks from 
AHRR-ZsGreen-transduced populations.  In contrast to the ZsGreen-AHRR- 
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population, the majority of the ZsGreen-AHRR+ population was positive for a 
combination of two hallmark Mk lineage markers, CD41a and CD42b (Figure 
8D). These cells also demonstrated characteristics of mature Mks including 
lobular nuclei and membrane blebbing at the surface of the cells (Figure 9A), and 
the ability to endoreplicate to 8N and 16N (Figure 9B). Quantitative PCR analysis 
of these cells also revealed robust upregulation of a spectrum of Mk-related 
genes including GPV, GPIIb, PF4, and CD62P (Figure 9C) that, as with the data 
presented in Figure 4, is used as a corollary to immunophenotyping data to 
further substantiate the hypothesis that these cells are megakaryocyte-lineage 
restricted.  Functionality of iPSC-derived Mks was assessed by their ability to 
produce platelets. Mature Mks were grown on an OP9 stromal layer for 3-5 days 
to allow for terminal Mk differentiation and platelet production. Cultures were 
initially gated using CD41a expression and demonstrated that iPSC Mk-derived 
platelets were similar to platelet populations from whole blood with respect to 
size (FSC), granularity (SSC), and the expression of GPIX and GPIb, two 
subunits of the GPIb/V/IX complex, that are characteristic of platelets (Figure 
9D). 
Collectively, these data suggest that production of erythroid-lineage cells 
is the default pathway of HPCs chronically stimulated with an AHR ligand. 
Inhibition of that default pathway results in an increase in the percentage of Mk-
lineage cells, an outcome that could reflect either a switch in cell fate decision to 
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favor Mk production or the maintenance of a small population of Mks during a 
decrease in the production of AHR-dependent erythroid-lineage cells (Figure 10). 
Optimization of iPSC directed differentiation to the megakaryocyte lineage 
To effectively analyze the relationship between AHR signaling and 
megakaryocyte specification, we sought to optimize the previously described 
differentiation strategy (Figure 1) such that the resultant cultures would produce a 
large subset of megakaryocyte lineage-committed cells. Importantly, these cells 
would not require experimental manipulation of the AHR signaling pathway in 
order to induce expansion of progenitors destined for Mk lineage commitment. To 
achieve this result, we sought to recapitulate Mk development within the bone 
marrow, including, but not limited to, the emulation of oxygen concentration and 
relative pH conditions of the osteoblastic niche (early megakaryocyte 
progenitors) and vascular niche (mature megakaryocytes primed for platelet 
production). Examples from the literature of similar differentiation strategies 
include an elegant optimization strategy that tested many conditions, including 
relative concentrations of megakaryocyte specifying cytokines and growth factors 
(Panuganti et al., 2013). Drawing on this work, we optimized our hematopoietic 
progenitor cell differentiation strategy such that an alternative differentiation 
program was utilized starting at Day 7, when the cells approximate early 
hematopoiesis (Figure 11). Cytokines that are known to preferentially cause 
megakaryocyte specification (TPO, IL-11, IL-3, and IL-6) were incorporated into 
Megakaryocyte Lineage Medium I, and the cells were incubated in hypoxic 
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conditions at pH 7.2 to best recapitulate the osteoblastic niche. These conditions 
were maintained until Day 12, when the cells were placed in normoxic conditions 
at a pH of 7.4 to best approximate the vascular niche. A similar cytokine cocktail 
was used in the media employed in this phase of the differentiation strategy, 
known as Megakaryocyte Lineage Medium II (Figure 11). At Day 18 of this 
revised protocol, we found that approximately 50% of the suspension cells that 
result are megakaryocyte lineage-committed, as shown by immunophenotyping 
data displaying CD41a/CD42b dual positivity of this discrete population (Figure 
12). Thus, we have created a megakaryocyte differentiation protocol that is 
optimized for mechanistic studies of AHR pathway dynamics throughout 
hematopoietic ontogeny.    
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AIM ONE DISCUSSION 
These results indicate that the AHR has a physiological and functional role 
in normal hematopoietic development and that modulation of the receptor in 
hematopoietic progenitor cells can direct cell fate. Demonstrated herein is a 
novel methodology for the directed differentiation of pluripotent stem cells in 
serum- and feeder cell-free, chemically-defined culture conditions into HPCs 
capable of final specification into Mk- and/or erythroid-lineage cells.  
In this work, the use of a non-toxic aryl hydrocarbon receptor agonist in a 
directed differentiation scheme dramatically increases the number of HPCs and 
resultant cells. This is an important finding in that, traditionally, the evolutionarily 
conserved AHR has been studied for its role in environmental chemical-induced 
toxicity, and in this system it is shown to be involved in the growth and the 
differentiation of at least two crucial blood cell types.  Following the addition of 
the potent AHR ligand FICZ to cultures, exponential expansion of HPCs was 
observed from half a million to 300 million cells in ten days. This logarithmic 
expansion of cells appears to be a function of decreased cell death and is 
consistent with previous studies that suggest that the AHR can control apoptosis 
(Marlowe et al., 2008, Matikainen et al., 2001).  
It is important to note that these results can be contrasted with work 
performed by Gasciewicz et al. in which AHR activation leads to exhaustion of 
the HSC pool as opposed to hematopoietic cell expansion. This apparent 
contradiction could reflect different stages in hematopoiesis (HSCs vs. HPCs) or 
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the nature of the ligand.  Considerable evidence also indicates that functional 
outcomes may differ when using different AHR ligands, for example TCDD vs. 
FICZ (Barouki et al. 2012).   
Interestingly, FICZ, the AHR ligand utilized throughout this work, is a 
photo-metabolite of tryptophan that has been described previously in the 
literature (Rannug et al., 1995).  Based on previous studies demonstrating the 
ubiquity of FICZ (Wincent et al., 2009) and taken together with our data 
demonstrating the activity of this ligand, it is possible that FICZ plays a role in 
regulating hematopoiesis in vivo, possibly in concert with other endogenous AHR 
ligands. The ability to expand HPCs with an AHR ligand also suggests that blood 
cell development may be affected by a variety of environmental ligands 
(Gasiewicz, Singh, and Casado, 2010, Lindsey and Papoutsakis, 2011).   
In addition to allowing for the exponential expansion of HPCs, the results 
indicate that AHR modulation is also involved in the further specification of both 
the erythroid and Mk lineages with AHR agonism permissive to the differentiation 
of erythroblasts and antagonism or downregulation of AHR leading to Mk 
specification. Although erythropoietin (EPO) and thrombopoietin (TPO) are the 
major drivers in RBC and platelet development, AHR may play a cytokine-
independent role in the development and specification of these lineages and 
warrants further study in this capacity. Alternatively, it may serve to alter the 
sensitivity of HPCs to either cytokine in culture, perhaps by actively suppressing 
megakaryocyte-associated genes or upregulating erythroid associated genes. 
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The proposed mechanism of the observed effect of AHR signaling in the context 
of HPC lineage determination will be further addressed in Aim 2.   
During the course of this work, derived putative progenitors were known to 
express markers of both the Mk and erythroid lineages.  A particularly striking 
outcome of these experiments is the development of a simple protocol for the 
rapid and highly efficient derivation of putative MEPs, which expand 
exponentially under AHR agonism.  In addition to the ability to answer basic 
biological questions concerning hematopoietic development, a useful outcome 
for this work will be the utilization of this in vitro platform for the production of 
blood products as the combination of AHR modulation with a completely 
chemically-defined and xenobiotic agent-free differentiation scheme makes Good 
Manufacturing Practice (GMP) production and clinical translation feasible.  Blood 
transfusion is an indispensable cell therapy, and the safety and adequacy of the 
blood supply are of national and international concern. An iPSC-based system, 
such as the one described here in which large numbers of cells can be produced, 
could allow for platelet transfusion without problems related to immunogenicity, 
contamination, or supply.  Furthermore, the fact that platelets contain no nuclear 
genetic material may mitigate some safety concerns usually associated with 
suggestions to transfuse or transplant iPSC-derived cells in humans. Finally, with 
the ability to optimize this differentiation strategy to increase the efficiency of 
megakaryocyte lineage specification, there now exists a platform by which to 
study AHR pathway signaling without the requirement for experimental 
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manipulation of the AHR early in the directed differentiation protocol. This allows 
for further experimentation that can introduce AHR agonism/antagonism at any 
desired time point and provide a defined temporal window with which to observe 
AHR pathway dynamics in multiple hematopoietic specifying cells.   
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AIM ONE FIGURES 
Aim 1, Figure 1: iPSC-derived hematopoietic progenitor cells (HPCs).  
iPSCs were passaged onto matrigel coated plates in the presence of RHO 
Kinase inhibitor and bFGF to retain pluripotency. Cultures at a low confluency 
were differentiated using the cytokines and growth factors described in the figure 
at discrete time points. A cytokine cocktail that causes HPC specification was 
added at Day 7, and this includes both TPO and EPO, resulting in a cell type that 
will ultimately be shown to express markers of both the erythroid and 
megakaryocyte lineages.  
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Aim 1, Figure 1 
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Aim 1, Figure 2: Multiple iPSC lines are differentiated towards HPCs 
Immunophenotyping of the suspension cell population that accumulates at 
~Day 10 of the differentiation protocol reveals a predominant population that is 
CD235a (glycophorin A) and CD41a (GPIIb) dual positive, proving that these 
cells mimic the putative MEP. These cells were established by directed 
differentiation of control, sickle cell anemia, and Bernard-soulier syndrome 
disease specific lines, providing evidence to their utility in studying the pathology 
of related disease. 
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Aim 1, Figure 2 
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Aim1, Figure 3: HPCs produce myeloid lineage colonies 
Colony forming cell assays from unsorted D15 non-adherent cell 
populations in which 28,000 cells per assay were grown in methylcellulose with 
hematopoietic growth factors for 12 days. Data are averages of three 
independent experiments and graphed as a percentage of total colonies formed 
+/- SD. (no statistical difference was noted between colony types).  
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Aim 1, Figure 3 
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Aim 1, Figure 4: HPCs express markers of megakaryocyte and erythroid 
lineage 
The genes for gamma globin (HBG), alpha globin (HBA), and beta globin 
(HBB), genes associated with the erythroid lineage, were expressed in Day 15 
HPCs (left panel). Concomitantly, the genes for platelet factor 4 (PF4), p-selectin 
(CD62P), and nuclear factor-erythroid 2 (NFE2), genes associated with the 
megakaryocyte lineage, were also expressed in Day 15 HPCs (right panel).  Data 
from three independent experiments were analyzed using the relative standard 
curve method, normalized to β-ACTIN expression. Error bars reflect the standard 
deviation. Asterisks indicate a significant increase in the mRNA. (*P <0.05.) 
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Aim 1, Figure 4  
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Aim 1, Figure 5: The AHR agonist FICZ inhibits apoptosis and allows for the 
exponential expansion of iPSC-derived HPCs 
(A) Representative FACS analysis of live vs. dead or dying cells 
(propidium iodide [PI] vs. Hoechst) from day 15 HPCs +/- FICZ. Plots were gated 
first in forward light scatter (FSC) vs. side light scatter (SSC) and then from that 
population for PI+ and PI- Hoechst+. (B) FICZ increases the population of live 
cells, as delineated by FSC and SSC, and decreases the number of 
compromised or apoptotic cells. For the live-cell gate, data are the average of 3 
independent experiments +/- SD: *P<.01. For the apoptotic cell gate, data are the 
average of 3 independent experiments +/- SD: *P<.02. (C) EdU proliferation 
assay comparing day 15 HPCs +/- FICZ. After FICZ stimulation on day 7, EdU 
incorporation into treated HPCs was significantly increased compared with 
untreated controls, indicative of increased proliferation. Data are the average of 3 
independent experiments +/- SD: *P<.01. (D) Representative phase-contrast 
images of HPC population +/- FICZ. (E) Growth curve of day 15 HPCs +/- 0.2µm 
of FICZ. Cells were counted manually using trypan blue exclusion. Graphical 
data and the associated statistics are the result of 3 independent experiments 
per group +/- SD. 
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Aim 1, Figure 5 
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Aim 1, Figure 6: AHR agonists induce CYP1B1 target gene expression in 
human iPSCs and HPCs 
(A) Western blot analysis for AHR and β-ACTIN protein expression in 
iPSCs and HPCs. (B) Quantitative PCR data of iPSCs and day 15 HPCs with 
and without 0.2µm of FICZ for 3 days. Expression is normalized to β-ACTIN 
levels. Data are the average of 3 independent experiments +/- SD: *P<.05, 
**P<.005.  
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Aim 1, Figure 6 
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Aim 1, Figure 7: iPSCs and HPCs are responsive to a spectrum of AHR 
agonists 
 (A) qPCR analysis of CYP1B1 in iPSC treated with TCDD or β-NF for 4 
days. Data are averages of duplicate wells +/- SEM and values are normalized to 
GAPDH. (B) qPCR analysis of CYP1B1 in HPCs treated with β-NF or FICZ. Data 
are averages of two independent experiments +/- SEM and values normalized to 
GAPDH.  
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Aim 1, Figure 7 
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Aim 1, Figure 8: AHR repression promotes megakaryocyte specification. 
(A) Schematic representation of a pHAGE2 lentiviral reporter construct 
containing the AHRR and ZsGreen under the control of the constitutive promoter 
Ef1α (pHAGE2-Ef1α-AHRR-IRES-ZsGreen). (B) Phase-contrast and fluorescent 
images of D30 HPCs after infection with a constitutively active ZsGreen control 
virus or pHAGE2-Ef1α-AHRR-IRES-ZsGreen. Large cells (megakaryocytes) are 
noted in the populations infected with the AHRR. (C) Graphical representation of 
the percentage of ZsGreen+ cells that express CD235a (erythroid lineage) or 
CD41a (megakaryocyte lineage) after mock or AHRR infection. Data are 
presented as means of 3 independent experiments +/- SD: *P<.005. (D) FACS 
analysis of AHRR-ZsGreen negative vs. positive fractions of hallmark 
megakaryocyte markers CD41a/CD42b. 
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Aim 1, Figure 8  
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Aim 1, Figure 9: Characterization and functional analyses of iPSC-derived 
megakaryocyte-lineage cells.  
(A) Wright-Giemsa stain of megakaryocytes produced via AHR 
antagonism. (B) Ploidy analysis of iPSC-derived megakaryocytes demonstrating 
endoreplication. (C) qPCR analysis comparing undifferentiated iPSCs vs. iPSC-
derived megakaryocytes for a spectrum of megakaryocyte-specific markers. 
Expression is normalized to β-ACTIN levels. Data are the average of 3 
independent experiments +/- SD. (D) FACS analysis comparing platelets in 
whole blood vs. iPSC megakaryocyte-derived platelets. Mature megakaryocytes 
were grown on an OP9 stromal layer for 3 to 5 days to allow for terminal 
megakaryocyte differentiation and platelet production. Cultures were initially 
gated using GPIIb (CD41a) expression and demonstrated that iPSC 
megakaryocyte-derived platelets were similar to platelet populations from whole 
blood with respect to size (FSC), granularity (SSC), as well as the expression of 
GPIX and GPIb, 2 subunits of the GPIb/V/IX complex, that are characteristic of 
platelets. Plots are representative of 2 independent experiments. 
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Aim 1, Figure 9 
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Aim 1, Figure 10: Model for AHR regulation of HPC expansion and 
differentiation 
  The data explored in Aim 1, Figures 1-9 inspire a defined model of AHR 
signaling throughout hematopoietic progenitor cell (HPC) expansion and 
differentiation. HPCs are expanded in the presence of an AHR agonist, FICZ, 
and will preferentially specify to the erythroid lineage with sustained AHR 
agonism in long-term culture. Alternatively, when AHR signaling is actively 
suppressed, so to is erythroid lineage commitment, with megakaryocyte lineage 
cells predominating.  
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Aim 1, Figure 10 
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Aim 1, Figure 11: Optimization of iPSC directed differentiation towards the 
megakaryocyte lineage 
 A megakaryocyte biased differentiation strategy of iPSCs was 
incorporated to produce megakaryocyte lineage cells without the requirement for 
AHR activation. This differentiation strategy is identical to the one described in 
Aim 1, Figure 1 from Day 0 to Day 6, but incorporates hypoxic conditions with a 
megakaryocyte defined cytokine cocktail (TPO, IL-3. IL-6, IL-11) and a pH of 7.2 
at Day 6. Conditions return to normoxia with a pH of 7.4 and a slightly altered 
cytokine cocktail (TPO, IL-3, IL-11, IL-9) at Day 11. Cells are typically harvested 
at Day 18 and express markers for megakaryocyte lineage commitment (Aim 1, 
Figure 12). 
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Aim 1, Figure 12: iPSC differentiation to the megakaryocyte lineage 
produces an abundance of lineage-restricted progenitors  
 From the directed differentiation strategy described in Aim 1, Figure 11, 
the cells at Day 18 are overwhelmingly megakaryocyte lineage committed, as 
assessed by flow cytometry for CD41a/CD42b. Plots are representative of 3 
independent experiments. 
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Aim 1, Figure 12 
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AIM TWO 
Our second aim is to explore the influence of the AHR in early 
megakaryocyte-lineage specification by using a megakaryocyte-biased 
hematopoietic differentiation protocol for the derivation of iPSCs.   
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AIM TWO METHODS 
Cell Line Acquisition, Cell Culture, and Media  
Meg01 cells were purchased from and cultured according to ATCC 
recommendations (ATCC, Manassas, VA). Briefly, Meg01 cells were maintained 
in RPMI Medium (Invitrogen) containing 5% FBS (Hyclone), 2 mM L-glutamine 
(Mediatech), 100 I.U. and 5 µg/ml Primocin (Invivogen, San Diego, CA) at 37°C 
with 5% CO2. Phorbol 12-myristate 13-acetate (PMA) was used to induce 
megakaryocyte maturation as previously described (Deutsch et al. 2000) at a 
concentration of 40 nM. 
iPSC generation and maintenance  
Induced pluripotent stem cells were generated as described previously (C. 
A. Sommer et al. 2009) (A. G. Sommer et al. 2012). Briefly, 4 mL of human 
peripheral blood was collected into a BD Vacutainer CPT Cell Preparation Tube 
and centrifuged to produce a buffy coat containing peripheral blood mononuclear 
cells (PBMCs). The buffy coat was collected and PBMCs cultured ex-vivo for 9 
days before transduced with the STEMCCA lentiviral vector. At Day 12 of culture, 
STEMCCA transduced PBMCs were plated onto mouse embryonic fibroblasts 
(MEFs) and cultured for roughly 30-40 days, when fully formed iPSC colonies 
were identified and separately harvested. Following successive passages onto 
irradiated MEFs (R&D, #PSC001), colonies were adapted to matrigel-coated 
tissue culture dishes in the absence of a feeder cell layer. IPSCs were then 
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cultured in mTESR1 media (StemCell Technologies, #05850) for all further 
passages.    
Creation of CRISPR/CAS9 targeted CYP1A1 reporter iPSCs 
Targeting of the CYP1A1 locus was achieved by co-transfection of the 
plasmids described (Figure 11A). Confluent iPSC cultures were pre-treated with 
10 µM Y-27632 (ROCK inhibitor) for 3 hours in mTESR1 medium. Cells were 
resuspended in 100 µL of P3 solution (Lonza) and added to a cuvette for the 
Lonza 4D Nucleofector at a density of 56 cells per cuvette. 2 µg of the CAS9 
vector and 3 µg of the Donor vector were added to the cell suspension and 
nucleofected using the CB-150 program. Immediately following nucleofection, 
cells were resuspended into fresh mTESR1 with 10 µM Y-27632 and plated onto 
one 10 cm plate (pre-treated with matrigel) and left at 37° in a low oxygen (5% 
O2) incubator. Cells were allowed to grow for 5 days before clones were selected 
for puromycin resistance by the addition of 0.7 µg/mL puromycin (ThermoFisher, 
#A1113802). Colonies were harvested as they appeared in culture and were 
passaged and maintained separately before screened by PCR for the integrated 
construct. 
PCR and Sanger Sequencing 
To validate proper targeting of the reporter construct to the CYP1A1 locus, 
two PCR products were amplified that flank the 5’ and 3’ ends of the reporter 
construct (respectively) and include elements of both the integrated cassette and 
the endogenous locus (Figure 11C). PCR was performed using recombinant Taq 
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polymerase (ThermoFisher, #10342) with primers for the 5’ amplicon (Forward: 
5’-ggtgggatttcctgcatcct -3’; Reverse: 5’- cttgtggccgtttacgtcg -3’) and 3’ amplicon 
(Forward: 5’- cctgcaggatctgatcagataacttcg -3’; Reverse: 5’- 
caggttgactaggctaagcagttcttg -3’) in separate reactions. PCR products were 
resolved by agarose gel electrophoresis and were 962 bp and 704 bp, 
respectively. Bands that appeared to be the proper size by electrophoresis were 
extracted and purified using the QiaQuick gel extraction kit (Qiagen, #28704) and 
submitted for Sanger sequencing to Genewiz, Inc. 
Generation of hepatocyte-like cells from iPSCs 
iPSC cultures were passaged using Gentle Cell Dissociation (GCD) 
Reagent (StemCell Technologies, #07174) to obtain a single cell suspension and 
counted using a hemocytometer. Cells were passaged onto matrigel-coated 
tissue culture dishes at a cellular density of 35 per well of a standard 6 well plate. 
After 24 hours, mTESR1 was replaced by media provided by the STEMdiff 
Definitive Endoderm Kit (Stemcell Technologies, #05110) and cultured according 
to manufacturer’s instructions for 5 days. At Day 5, GCD was used to make a 
single cell suspension and the cells were passaged at a ratio of 1:6 onto matrigel 
coated 6 well plates. The media for all subsequent days was an SFD base 
(Gouon-Evans et al. 2006) with ascorbic acid (50 μg/mL) and monothioglycerol 
(4.5e-4 M). Media for days 5 and 6 included Activin A (50 ng/mL), BMP4 
(10ng/mL), FGF2 (10 ng/mL), and VEGF (10ng/mL). The media for days 7-12, 
days 13-18, and days 19-25 were adapted directly from a previous manuscript 
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(Wilson et al. 2015). Days 7-12: BMP4 (50ng/mL), FGF2 (10ng/mL), VEGF 
(10ng/mL), EGF (10ng/mL), TGFa (20ng/mL), HGF (100ng/mL), and 0.1 µM 
Dexamethasone; Days 13-18: FGF2 (10ng/mL), VEGF (10ng/mL), EGF 
(10ng/mL), HGF (100ng/mL), Oncostatin M (20ng/mL), Vitamin K (6 µg/mL), 1.5 
µM gamma secretase inhibitor, 0.1 µM Dexamethasone, and 1% DMSO; Days 
19-25: HGF (100ng/mL), Oncostatin M (20ng/mL), Vitamin K (6 µg/mL), and 0.1 
µM Dexamethasone. Cells were kept in a low oxygen (5% O2) incubator 
throughout the differentiation.   
Generation of hematopoietic progenitor cells from iPSCs and treatment 
with 6-formylindolo(3,2-b)carbazole (FICZ) 
Hematopoietic progenitor cells were derived from induced pluripotent stem 
cells using our previously published protocol (Smith and Rozelle et al., 2013). 
Briefly, iPSCs seeded on matrigel plates were exposed to cytokine conditions 
that promoted mesoderm specification, followed by a hemogenic endothelial-like 
phenotype, and, finally, hematopoietic progenitors that dis-adhered from the 
matrigel substrate and were dual positive for CD41a and CD235a (data not 
shown). At Day 7 of the protocol, cells were treated with escalating doses of 
FICZ, at a range of 10-8 to 10-4 M, and kept in this condition for 5 days. Cells 
were harvested at Day 12, at which point, lysates were created for luciferase 
assays as well as RNA extraction and kept at -80° C.  
RNA extraction and quantitative PCR 
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RNA was extracted using the RNeasy Mini Kit (Qiagen, #74104). At the 
time of harvest, cells were washed with PBS, spun for 5 minutes at 300 x g, and 
the pellet was collected in 350 µL of Buffer RLT. RNA extraction proceeded 
according to manufacturer instructions. RNA was eluted into 30 µL of 
endonuclease-free H2O and purified with DNAse using the DNA-free DNA 
Removal kit (ThermoFisher, #AM1906). Once purified, 20 µL of sample was used 
to generate cDNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, #4368814). RNA samples were quantified using a 
NanoDrop Lite (Thermo Scientific) Spectrophotometer, and cDNA samples were 
diluted to 1 µg/µL. Quantitative PCR was carried out using the Taqman Universal 
Master Mix (Thermo Scientific) and primers for CYP1A1 (Hs01054797_g1), 
CYP1B1 (Hs002382916_s1), MPL (Hs00180489_m1),  and β-ACTIN 
(Hs99999903_m1) were used. Samples were run in triplicate and, where 
appropriate, were analyzed by Student’s t test to assess significance between 
groups. 
Flow Cytometry 
Flow cytometry was performed at Days 5, 14, and 25 of hepatocyte 
specification. For Day 5, 35 cells were stained per condition, and the C-KIT 
antibody (Biolegend, #313206) and CXCR4 antibody (Invitrogen, #MHCXCR404) 
were used at a concentration of 5 µL per 16 cells. Staining was performed on ice 
for 30 minutes. For Days 14 and 25, cells were fixed in 1.6% paraformaldehyde 
before staining. Primary antibodies for AAT (Santa Cruz, #sc-59438) and FOXA1 
  
71 
(Santa Cruz, #101058) were added at 1:100 ratio in Saponin Buffer (2% FBS, 1x 
Permeabilization Wash Buffer (Biolegend, #421002)) and incubated at room 
temperature for 30 minutes. Secondary antibodies for AAT (Jackson 
Immunoresearch, #115-605-205) and FOXA1 (Jackson Immunoresearch, #115-
545-206) were added at a dilution of 1:500 and incubated at room temperature 
for 30 minutes. All samples were resuspended in PBS with 0.5% BSA for 
analysis. For immunophenotyping of hematopoietic progenitors, 35 cells were 
stained per condition with antibodies for CD41a (BD Pharmingen, #559777), 
CD42b (BD Pharmingen, #555473), and C-MPL (BD Pharmingen, #562199). 
Cells were stained in PBS with 0.5% BSA for 30 minutes on ice in 100 µl of total 
volume and resuspended in 1 ml of buffer. Cells were then centrifuged at 3300 
RPM for 5 minutes and resuspended in buffer supplemented with 1 µg/ml 
propidium iodide. All analysis was performed on a BD FACScalibur machine. 
Mean fluorescence intensity (MFI) was determined for 3 independent 
experiments by finding the geometric mean of histogram plots showing relative 
C-MPL expression across conditions.  
Luciferase assays 
To assess luciferase expression, cells were harvested and counted by 
hemocytometer to ensure 15 cells per 20 µL of 1x lysis buffer from the 
commercially available luciferase assay system (Promega, #E1500). Upon 
sufficient lysis, samples were stored at -80° C until all time points were collected. 
Samples were then thawed on ice and assayed by adding 20 µL per well of a 96 
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well plate, followed by addition of 100 µL of luciferase assay reagent (Promega) 
and immediate analysis of luminescence in a Tecan Infinite M1000 microplate 
reader.  
Digital Gene Expression Analysis 
 RNA harvested from Day 23 of the directed differentiation protocol 
outlined in Aim 1, Figure 11, were analyzed via single cell RNA barcoding and 
sequencing (SCRB-seq), a high throughput method to create a full cDNA library 
from small RNA concentrations (Soumillon et al. 2014). SCRB-seq converts 
poly(A)+ mRNA to cDNA using a template-switching reverse transcriptase and 
sequenced. Computational and statistical analyses were performed using 
R(v.3.2.1) and Bioconductor (https://www.bioconductor.org/). Pairwise 
differential expression analysis was performed with the edgeR package 
(https://bioconductor.org/packages.release/bioc/html/edgeR.html). 
Fibroblast differentiation and small molecule treatment 
iPSCs were seeded on matrigel coated 12 well plates at a density of 35 
cells per well and left in mTESR medium for 24 hours. Fibroblast induction media 
(IMDM, 10% FBS, 2mM l-glutamine, and 100 µg/mL primocin (Invivogen, #ant-
pm-1)) was added for 2 days, followed by small molecule treatment for exactly 24 
hours before cells were harvested for luciferase and qPCR assays. Small 
molecule AHR modulators were added at the following concentrations: TCDD, 
1nM; CH223191, 10µM; benzo[a]pyrene, 1µM; benzo[e]pyrene, 1µM; FICZ, 
10µM; indoxyl sulfate, 100µM. TCDD, benzo[a]pyrene, benzo[e]pyrene and 
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indoxyl sulfate were acquired from Sigma; FICZ was purchased from Santa Cruz 
Biotechnology; CH223191 is kindly provided by Dr. Mike Pollastri, Northeastern, 
University.   
Statistical analyses 
Results are presented as the mean ± the standard error of the mean.  
Statistical significance was confirmed using the Student’s t-test. 
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AIM TWO RESULTS 
C-MPL expression is attenuated by AHR signaling in iPSC derived Mk 
progenitors and immortalized megakaryoblasts 
Following our discovery that modulation of the AHR signaling pathway causes 
lineage commitment of our iPSC derived HPCs, we began to explore the 
mechanism by which AHR suppression facilitates megakaryocyte specification. 
Using an immortalized megakaryoblast cell line (Meg01), we determined that C-
MPL, the receptor for Thrombopoietin, is significantly downregulated at both the 
cell surface (Figure 2) and transcript (Figure 3) level in the presence of the AHR 
agonist FICZ. The Meg01 immortalized line is known to undergo megakaryocyte 
maturation as a function of treatment with a phorbol ester, PMA (Deutsch et al., 
2000). This compound, a known activator of protein kinase C (Ballester and 
Rosen, 1985), was shown to induce a large proportion of Meg01 cells towards 
CD41a/CD42b dual positive immunophenotype (Figure 1), a marker of 
megakaryocyte lineage commitment. Indeed, C-MPL expression was attenuated 
at the cell surface in both untreated and PMA induced cultures as a consequence 
of FICZ treatment, showing the fidelity of this result in both early and late stage 
megakaryoblasts (Figure 2). 
 Furthermore, transcriptional profiles of the canonical AHR target gene 
CYP1B1 was compared to that of MPL in the context of the same experimental 
conditions. In uninduced cultures, FICZ treatment significantly increased 
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CYP1B1 transcript while simultaneously causing MPL levels to decrease with 
respect to the vehicle control (Figure 3). PMA induction led to a significant 
increase in MPL transcription versus the vehicle control, but did not cause a 
statistical increase in CYP1B1. With the addition of FICZ to these cultures, 
CYP1B1 was once again significantly upregulated while MPL levels were 
similarly diminished (Figure 3). This critical finding was extended to our iPSC 
derived HPCs, which also exhibited attenuated MPL transcription and cell 
surface expression when treated with FICZ (Figures 4 and 5). Importantly, 
treatment with StemRegenin 1 (SR1), a known AHR antagonist (Boitano et al., 
2010), produced a significant increase in MPL transcript, providing more 
evidence that the observed variance in MPL expression is an AHR-dependent 
effect (Figure 5). With respect to surface expression, FICZ was shown to almost 
completely abolish C-MPL as compared to the DMSO negative control (Figure 4). 
To analyze our findings by flow cytometry, we plotted the mean fluorescence 
intensity (MFI) of three independent experiments and discovered that while SR1 
treatment seemed to trend towards an increase in C-MPL, this was a statistically 
insignificant observation when compared to DMSO; only the FICZ treatment 
condition was significantly different with respect to the vehicle (Figure 4). The 
implication of this work seems to be that AHR activation suppresses C-MPL at 
the transcript and surface level, but that antagonism may not ultimately affect 
surface level expression of C-MPL.  
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Manipulation of the AHR pathway leads to iPSC-derived megakaryocyte 
expansion and causes a subset of megakaryocyte genes to be differentially 
expressed 
As outlined in Aim 1, the megakaryocyte specifying iPSC directed 
differentiation protocol causes megakaryocyte lineage committed cells to 
predominate the culture by day 18 (Aim 1, Figures 10 and 11). Starting at this 
crucial time point, cells were treated with either FICZ or CH223191, a known 
AHR antagonist (Zhao et al, 2010), and collected 5 days later (Day 23). Most of 
the CD41a+ cells were lost by day 23, revealing a tight temporal window at which 
these cells are expanded and continue to thrive (Figure 6). Surprisingly, the 
deterioration of the CD41a+ compartment wasn’t observed with prolonged 
treatment with CH223191. Instead, these cells were maintained, giving further 
evidence that AHR inhibition leads to megakaryocyte lineage bias (Figure 6). 
Because of the discrepancy between the proportion of CD41a+ cells in the 
CH223191 condition versus the DMSO and FICZ conditions, only DMSO and 
FICZ were included in subsequent digital gene expression (DGE) analysis 
(Figures 7-10). DGE is a technique that employs single cell RNA barcoding and 
sequencing (SCRB-seq) to generate an entire cDNA library from a small starting 
sample of purified RNA (Soumillon et al., 2014). Analysis of the transcriptomic 
data revealed MPL expression to be modulated with FICZ treatment as expected 
(Figure 7). The DGE data also revealed a subset of megakaryocyte (Figure 8) 
and erythroid (Figure 9) genes whose expression was modulated in the FICZ 
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treatment paradigm as well as CDKN1A, a direct target of TPO signaling (Figure 
10). As expected, the megakaryocyte associated genes (Figure 8) were 
downregulated by FICZ treatment and included PF4, or platelet factor 4, a 
chemokine secreted by platelets to modulate their response to heparin (Stringer 
and Gallagher, 1997), SELP, or P-Selectin, a cell adhesion molecule (CAM) 
expressed by activated platelets (Cambien and Wagner, 2004, Vestweber and 
Blanks, 1999), and GP9, or glycoprotein IX, a glycoprotein that makes up one 
subunit of the von Willebrand receptor complex (GPIb/V/IX) on megakaryocytes 
and platelets (Roth et al., 1988). Similarly, it was found that erythroid markers 
were differentially expressed as a consequence of FICZ treatment, but these 
targets were actually upregulated as compared to the vehicle control (Figure 9). 
These targets were ALAS2, or delta-aminolevulinate synthase 2, a 
mitochondrially localized enzyme that catalyzes the first step in heme 
biosynthesis (Astner et al., 2005), and HBA2, or hemoglobin alpha 2, a variant of 
alpha globin that is located within the human alpha globin gene cluster (Higgs et 
al., 1989). Finally, there was an observed decrease of the transcript encoding 
CDKN1A, the gene for p21, a protein that regulates the cell cycle and, 
importantly, is a direct target of TPO signaling (Matsumura et al., 1997) (Figure 
10). These results indicate a role in AHR signaling that leads to a battery of 
genes that are differentially expressed to suppress megakaryocyte lineage 
commitment in iPSC derived megakaryocyte progenitors. 
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Vector design, construction, and validation of a CYP1A1 reporter iPSC line 
Using a CRISPR/CAS9 system for genome editing, we next sought to 
create an endogenous reporter of AHR activity in an iPSC line by targeting the 
CYP1A1 locus. CYP1A1 is a canonical target of AHR signaling, one that is widely 
used to report on AHR activity in multiple cell and tissue types both in vivo and in 
vitro (Bock and Kohle, 2009). This cell line would offer the ability to temporally 
map AHR activation throughout iPSC directed differentiation to discrete 
hematopoietic populations, culminating in megakaryocyte lineage specification.  
To create an endogenous reporter of AHR activity in an iPSC line, a 
CRISPR/CAS9 system was engineered to target the CYP1A1 locus. A plasmid 
was created that expresses a reporter cassette of enhanced green fluorescent 
protein (eGFP) and firefly luciferase bifurcated by an internal ribosomal entry 
sequence (IRES) to allow for each reporter gene to be expressed on the same 
transcript (Figure 11A). Downstream of this cassette is a puromycin resistance 
gene (PURO) driven by a constitutive promoter for murine phosphoglycerate 
kinase (PGK) to allow for antibiotic selection. This reporter sequence does not 
include a 5’ regulatory region, but rather is flanked by homology arms that 
facilitate recombination directly downstream of the CYP1A1 transcription start 
site in the endogenous locus. Using this strategy, reporter expression is 
exclusively driven by the CYP1A1 promoter, a regulatory region that includes 10 
distinct AHR response elements (AHREs) (Kress, Reichert, and Schwarz, 1998). 
A guide RNA sequence (gRNA) was developed using a publically available web 
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resource (crispr.mit.edu) created and distributed by the Zhang Lab at the 
Massachusetts Institute of Technology (Cong and Zhang, 2015). The guide RNA 
shares sequence homology with a 23 base pair region exactly 8 base pairs 
downstream of the CYP1A1 start codon (5’-CCCAATCTCCATGTCGGCCACGG-
3’) that includes a 3 base pair protospacer adjacent motif (PAM) sequence that is 
necessary for CAS9 binding (Figure 11B). The guide RNA and CAS9 coding 
regions were included on the same plasmid, separate from the plasmid 
containing the reporter construct, each with a dedicated constitutive promoter 
(Figure 11A).   
Co-transfection of the two engineered plasmids produced a series of 
puromycin resistant clones that were then screened for the inserted reporter 
sequence within the CYP1A1 locus. Validation was accomplished by a PCR 
strategy that creates two distinct amplicons at the flanking regions of the 
integrated cassette. Using this strategy, each amplified region contains elements 
of the CYP1A1 endogenous locus that is not included in the homology arms as 
well as elements of the donor sequence (Figure 11C). Successful PCR 
amplification of these regions can only be achieved in properly targeted clones 
(Figures 11D and 11E) and Sanger sequencing confirms that each amplicon 
includes genomic regions of the CYP1A1 locus as well as elements from the 
donor construct (Figure 12).  
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CYP1A1 reporter iPSCs respond to FICZ in a dose-dependent manner 
To achieve functional validation of the properly targeted clone, we used a 
previously published, directed differentiation protocol for the production of 
hematopoietic progenitors of the megakaryocyte and erythroid lineages (Smith 
and Rozelle et al., 2013). Our previous work revealed that activation of the AHR 
pathway with 6-formylindolo(3,2-b)carbazole (FICZ) in this population causes 
exponential expansion and increased viability in culture (Smith and Rozelle et al., 
2013). Having proven this population’s responsiveness to AHR agonism, we 
treated hematopoietic progenitors derived from a CYP1A1 targeted clone with 
escalating doses of FICZ for 5 days. FICZ treatment increased transcript 
expression of CYP1A1 in a dose-dependent manner, and this result was 
observed in both the parental iPSC line as well as the CYP1A1 targeted clone 
(Figure 13A). These cultures were also assayed for luciferase expression, and 
unlike CYP1A1 transcript expression, only the CYP1A1 targeted line displayed 
luciferase bioluminescence that increased significantly with each successive 
FICZ dose (Figure 13B). This work confirms that the CRISPR/CAS9 targeted 
clone faithfully reports on AHR activation through a functional output of luciferase 
expression.  
Mapping of AHR activity throughout human hepatocyte specification using 
CYP1A1 targeted iPSCs 
 To fully utilize the CYP1A1 targeted iPSC line, we differentiated these 
cells towards the hepatocyte lineage in order to showcase the potential of this 
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reagent to provide a temporal map of AHR activation in a variety of cellular 
contexts. Multiple studies have reported on the AHR response to environmental 
ligands in primary liver, and have displayed a baseline level of CYP1A1 protein 
expression even in the absence of toxin exposure (Santostefano et al., 1999). 
Thus, in order to confirm the utility of this cell line, we sought to recapitulate 
these results in an in vitro context using a previously described protocol for 
directed differentiation to hepatocyte specification (Leung and Murphy, 2016, 
Wilson et al., 2015). Using this strategy, we successfully produced cells with 
definitive endodermal markers (CXCR4 and CKIT) after 5 days of differentiation, 
and proceeded to incorporate a cytokine cocktail including FGF2 and Activin A to 
produce early hepatocyte progenitors at Day 14, as indicated by observed dual 
positivity for Alpha 1 Anti-trypsin (AAT) and FoxA1 (Figure 14A). Cultures were 
subsequently exposed to a specified media containing Hepatic Growth Factor 
(HGF) and Oncostatin M, and at Day 25, the AAT+/FoxA1+ population had 
increased substantially (63.7%) (Figure 14A). Micrographs taken at Days 5, 14, 
and 25 of differentiation show the progressive change in cellular morphology of 
these cells as they formed a homogenous 2D monolayer (Day 5) followed by a 
heterogenous population where polygonal hepatic-like cells began to emerge 
(Day 14) and, finally, an adherent cellular layer dominated by granular, polygonal 
cells with distinct, sinusoidal-like boundaries (Day 25) (Figure 14B). The CYP1A1 
reporter clone was differentiated in parallel with the parental iPSC line, and 
luciferase-dependent bioluminescence was assayed at each timepoint 
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throughout the hepatic differentiation. Undifferentiated cells (Day 0) as well as 
CXCR4+/CKIT+ definitive endoderm (Day 5) produced low levels of CYP1A1-
driven luciferase, but a marked increase in luciferase expression was observed in 
hepatocyte progenitors (Day 14) and, more significantly, early hepatocytes (Day 
25) (Figure 14C). Interestingly, the discrepancy seen between these two final 
time points is highly correlated to the relative abundance of AAT+/FoxA1+ dual 
positive cells within these cultures, suggesting that AHR activation occurs 
exclusively in this discrete population. The ability of CYP1A1 targeted iPSCs to 
faithfully report on patterns of activation previously reported in primary cells is an 
early indication of the utility of this cell line in mimicking in vivo ontogeny and 
providing an easily accessible model system upon which to study this highly 
ubiquitous pathway.   
CYP1A1 reporter iPSC-derived fibroblast-like cells respond to putative AHR 
ligands 
With the evolution of the AHR field, culminating in the description of endogenous 
roles of the AHR in the absence of classical, environmentally derived ligands, the 
value of an iPSC clone with the capacity to report on AHR activation is 
dependent upon its sensitivity to multiple small molecule compounds previously 
shown to affect AHR signaling (Busbee et al., 2013, Murray, Patterson, and 
Perdew, 2014, Stejskalova, Dvorak, and Pavek, 2011). To assess the ability of 
the CYP1A1 targeted cell line to respond to exogenous and proposed 
endogenous AHR ligands, we ran a chemical screen and assayed for luciferase 
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dependent luminescence at 24 hours after dosing. Due to the observed lack of 
AHR-dependent luciferase expression in the undifferentiated state (Figure 14C; 
Day 0 timepoint) we exposed iPSCs to a simplified media over the course of two 
days that quickly altered the cellular morphology to a fibroblast-like appearance 
(Figure 15A). These cells had detectable luminescence in the naïve (untreated) 
condition (Figure 15B), whereas undifferentiated cells had an indistinguishable 
expression profile to that of the parental iPSC line (Figure 14C; Day 0 time point). 
Our chemical screen incorporated known environmental ligands, including TCDD 
and benzo-[a]-pyrene, as well as endogenous agonists’ indoxyl sulfate and FICZ, 
and a potent AHR antagonist, CH223191 (CH) (Zhao et al., 2010). While 
treatment with DMSO alone did not elicit an AHR response, TCDD induced a 
significant response that was completely occluded by the presence of CH223191 
(Figure 15B; TCDD/CH condition). Both of these compounds are known to affect 
gene expression in an AHR dependent fashion, and CYP1A1 transcript level 
expression mirrored this result (Figure 15C). Further, the polycyclic aromatic 
hydrocarbon benzo[a]pyrene induced AHR activity while benzo[e]pyrene, a 
structurally similar compound previously shown to have very little affinity for AHR 
in the cytoplasm (Shimada et al., 2002), had no effect. Finally, the tryptophan 
derivatives indoxyl sulfate and 6-formylindolo(3,2-b)carbazole (FICZ) also proved 
efficacious in this model system.  
 Upon proper validation of the CYP1A1 reporter iPSC line, the relative 
luminescence (an indices of endogenous AHR activity) was measured 
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throughout multiple discrete timepoints of the megakaryocyte differentiation 
protocol (Aim 1, Figure 11). At Day 11, at which the cells are not yet 
megakaryocyte lineage-restricted but are still putative HPCs, the CYP1A1 
luciferase signal was at its peak, and subsequently diminished as the cells 
specify towards the megakaryocyte (Days 15, 18, and 20) (Figure 16A). 
Concomitantly, MPL transcript expression is at its highest at these same time 
points, as would be expected for cells in a step-wise megakaryocyte 
differentiation program (Figure 16B). These findings reflect the endogenous 
regulation of AHR signaling and the subsequent implications on the ability for 
these cells to effectively transcribe MPL. 
 AHR expression at both the protein and transcript levels was not assayed 
throughout this differentiation protocol. As such, the results presented in Figure 
16 could be susceptible to changes in the total AHR protein content available to 
the cells at each distinct time point. Further work that examines AHR expression 
can allow for the results in Figure 16 to be normalized to available AHR content. 
Indeed, Aim1, Figure 6 addresses this question by using immunoblotting to 
quantify AHR protein within iPSC-derived HPCs, finding the AHR to be 
undetectable before Day 30 of the differentiation. Despite this, CYP1B1 
transcription was still affected by FICZ treatment at earlier timepoints, suggesting 
that very small levels of AHR could still produce a significant amount of 
transcriptional changes that are AHR-dependent. Further work in the context of 
the AHR temporal map will be important to address this issue.  
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 The differential luciferase output observed throughout the 
megakaryocyte differentiation reported in Figure 16A is caused by the 
transcriptional machinery that regulates the expression of CYP1A1, which is 
almost exclusively driven by the AHR (Bock and Kohle, 2009). This is a temporal 
map of endogenous AHR activity, then, and is particularly interesting in that there 
are no known ligands that are added to the culture conditions throughout the 
differentiation in this particular experiment. Thus, the possibility exists that AHR 
ligands are present within the culture, and that the production and degradation of 
these ligands play an important role in the endogenous regulation of AHR activity 
that is observed. Of the tryptophan derived endogenous ligands that are reported 
in the literature, kynurenine is found in human sera (Hubbard et al, 2015) and 
could, potentially, play an important role in the regulation of megakaryopoiesis 
within the bone marrow. To properly examine this possibility, the enzymes that 
convert tryptophan to kynurenine, tryptophan (2,3)-dioxygenase (TDO) and 
indoleamine (2,3)-dioxygenase (IDO), could be directly measured in the culture, 
or the total tryptophan concentration could be compared to kynurenine levels and 
the ratio between the two correlated to the temporal map outlined in Figure 16A. 
Alternatively, AHR activation could be correlated to oxidative stress, as 
previously reported in the context of human keratinocytes (Xiao et al, 2015), 
providing a ligand-independent pathway to modulation of the AHR within this 
system. Multiple hypotheses can be drawn from the results in Figure 16A and 
further work can help elucidate the mechanism by which the AHR is modulated.  
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  Finally, as the AHR temporal map presented in Figure 16A pertains to the 
transcript levels of MPL in Figure 16B, there does not seem to be a direct inverse 
relationship between AHR upregulation and suppression of MPL transcription at 
each discrete timepoint. While it is clear that MPL transcript expression is 
significantly upregulated at Day 20 with respect to Day 11, and that this 
correlates with downregulation of AHR activity, the MPL transcript expression 
increases as would be expected in cells differentiating towards the 
megakaryocyte lineage, and this includes when AHR activity is at its peak at Day 
11. It is known that the MPL promoter contains binding sites for both GATA1 and 
Ets Family transcription factors (Kaushansky, 2005), perhaps overwhelming 
AHR-dependent regulation of MPL in this system, if indeed these factors are 
highly expressed. This possibility makes the mechanism of the endogenous 
regulation of the AHR within this differentiation schema even more important, as 
it is imperative to understand why experimentally delivered small molecule AHR 
modulators can efficiently disrupt MPL transcription while AHR modulation 
implicit in the culture conditions themselves do not have as potent of an affect.   
The results presented in this Aim are an important first step in elucidating 
the mechanism by which AHR suppression promotes megakaryocyte lineage 
specification and suggests that the AHR regulates TPO signaling by controlling 
the extent to which C-MPL is present on the surface of hematopoietic 
progenitors. 
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AIM TWO DISCUSSION 
 
Thrombopoietin (TPO) is the major specifying cytokine of megakaryocyte 
specification and maturation (Drachman et al., 1997). The degree with which 
megakaryocyte production is TPO dependent was first revealed using animal 
models with loss of function mutations in both thpo, the gene that encodes TPO, 
and mpl, the gene that encodes C-MPL, the dedicated TPO receptor. As 
expected, these mice lack megakaryocytes almost entirely and are severely 
thrombocytopenic; amelioration of this defect is only achieved through stem cell 
transplant from a wild type donor (Alexander et al., 1996, Fox et al., 2002). 
Interestingly, despite this treatment being the sole method for obviating the 
megakaryocyte-associated phenotype, researchers have discovered that the 
engraftment potential of donor HSCs is significantly reduced in recipient mice 
that lack proper TPO function (Fox et al., 2002). This finding has encouraged 
multiple studies that definitively show an important, conserved role of TPO 
signaling in the maintenance and expansion of primitive hematopoietic 
progenitors (Alexander et al., 1996, Ku et al., 1996). Concomitantly, the AHR has 
been shown to be endogenously expressed in HSCs (Singh, Casado, et al., 
2009) and has been linked to the regulation of signaling cascades that are 
implicit in nominal hematopoiesis (Singh, Wyman, et al., 2009). Indeed, AHR 
signaling has been shown to promote quiescence in human CD34+ 
hematopoietic progenitors, most notably through experimental antagonism with 
SR1, a well characterized inhibitor of the AHR pathway (Boitano et al., 2010). 
  
88 
SR1 significantly increases the CD34+ fraction, and this finding has spurred a 
clinical trial for its utility as a potential mechanism by which to expand cord blood 
derived hematopoietic progenitors such that clinical recipients would only require 
material from one donor source (Wagner et al., 2016). The parallel functionality 
of TPO activation and AHR antagonism in the context of the HSC gives rise to 
speculation that AHR signaling may regulate the TPO pathway, perhaps by 
directly suppressing the transcription of factors that are critical to TPO function. 
This hypothesis would not be without precedent in the literature, considering new 
evidence of the AHR transcriptional regulation of RUNX1 (Stanford 2015), a 
transcription factor involved in the differentiation of HSCs. RUNX1 functions 
primarily in a complex with GATA1, and this complex has been implicated in 
causing C-MPL expression to increase in accordance with megakaryocyte 
lineage-commitment (Goldfarb, 2009). Therefore, the transcriptional repression of 
MPL through AHR agonism that is described in this work may be mediated 
through a RUNX1-dependent mechanism, but further experimentation is needed 
to give this hypothesis any credence. Further, this affect may explain the 
erythroid bias seen in the HPCs maintained in culture with sustained AHR 
agonism (Aim 1), considering that TPO is included in the cytokine cocktail, and 
the cells, presumably, have decreased sensitivity to this cytokine as a result. 
Through the use of Digital Gene Expression (DGE) analysis, possible 
alternative mechanisms for AHR suppression of megakaryocyte cell fate were 
revealed. The most striking of these were the genes that were upregulated in the 
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FICZ condition that are involved in heme catabolism (ALAS2) and the expression 
of hemoglobin variants (HBA2). AHR signaling has previously been shown to be 
upregulated in primary erythroid progenitors known to undergo γ/β-globin 
switching by transcriptomic analysis (Li et al., 2012). Thus, the observed AHR-
dependent erythroid lineage bias in hematopoietic progenitors may be at least 
partly due to AHR mediated heme biosynthesis. Additionally, the other 
megakaryocyte-associated gene targets shown to be downregulated by FICZ 
treatment (PF4, SELP, and GP9) may be indicative of links to NF-κB signaling 
(SELP; (Pan and McEver, 1995)) and AHR regulation of RUNX1 co-factors’ FLI1 
(PF4, (Tijssen et al., 2011)) and GATA1 (GP9, (Tijssen et al, 2011)). Indeed, the 
extent to which AHR signaling exhibits cross-talk with other signaling cascades is 
vast, making it likely that multiple factors are both directly and indirectly regulated 
by FICZ in our megakaryocyte differentiation platform (Goel and Mercurio, 2013, 
Pickup, Novitskiy, and Moses, 2013). Finally, the decreased expression of 
CDKN1A, a cell cycle regulator and direct gene target of TPO (Matsumura et al., 
1997), gives further credence to the hypothesis that the AHR functions to disrupt 
this cytokine pathway, both by suppressing the expression of its dedicated 
receptor (C-MPL) and blocking expression of downstream targets.      
 Multiple bioassays have been developed to study AHR signaling in distinct 
cellular subtypes. These systems’ utility has mainly been in the identification of 
environmental ligands (Han, Nagy, and Denison, 2004) and, recently, the 
discovery of proposed endogenous ligands that range from the tryptophan 
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derivatives FICZ (Nuti et al., 2014, Wei et al., 1998) and indoxyl sulfate 
(Schroeder et al., 2010), to bilirubin, a natural product of heme catabolism 
(Phelan et al., 1998, Togawa, Shinkai, and Mizutani, 2008) and the arachadonic 
acid metabolites prostaglandin G (Seidel et al., 2001) and lipoxin A4 (Machado et 
al., 2006). Perhaps the most widely utilized experimental reporter is the pGudLuc 
vector, of which multiple iterations have been reported in the literature (Han, 
Nagy, and Denison, 2004). This vector was created by incorporating a 482 base 
pair segment of the murine cyp1a1 promoter with 4 AHREs (also known as 
Dioxin Response Elements, or DREs) within the mouse mammary tumor virus 
(MMTV) promoter, with luciferase expression as the functional readout. Since its 
inception (Garrison et al., 1996), this reagent has been optimized for better 
stability (Han, Nagy, and Denison, 2004) and used by many groups to assess 
ligand responsiveness in immortalized cell models (Gustavsson et al., 2004, 
Murray, Yang, and Sherr, 2006).    
The endogenous reporter of AHR activity described in this work 
represents a significant technological advancement that is highly specific and 
accessible to researchers with various expertise. Unlike immortalized cell lines 
with stable transfection of pGudLuc, this iPSC line has a targeted integrant 
directly downstream of the CYP1A1 transcription start site. Despite observations 
in the literature of off-target CRISPR/CAS9 cutting (Xiao-Hui Zhang et al., 2015), 
the functional data presented herein substantiates our hypothesis that little to no 
off-target integration of the reporter construct exists in this particular case. We 
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hypothesize, then, that this reporter line is isogenic to an in-house iPSC control 
and can be efficiently differentiated to multiple cellular lineages. Transcript-level 
expression of CYP1A1 in the targeted line upon FICZ treatment (Figure 13) 
proves that endogenous CYP1A1 is not knocked-out as a result of genomic 
integration, making it likely that the reporter construct is hemizygously expressed.  
This would indicate that this clone has a single integrant in the exact genomic 
location that AHR:ARNT dimers naturally modulate CYP1A1 gene expression. 
This system avoids random integration of an artificial promoter driven construct 
that could be expressed in multiple genomic locations and could potentially affect 
endogenous gene expression in unknown ways. It also uses the entire CYP1A1 
promoter to drive expression, utilizing potentially complex interactions and gene 
expression profiles dependent on distal cis elements that cannot be conveyed by 
transfection of reporter plasmids. TCDD exposure, for example, is known to 
affect local chromatin structure in promoting endogenous CYP1A1 expression 
(Okino and Whitlock, 1995) and selective ligands may alter AHR:ARNT dimer 
binding, causing AHRE-independent control of the CYP1A1 promoter (DeGroot 
and Denison, 2014). Thus, this cell line will be critically important in future studies 
that implicate novel small molecule compounds as AHR modulators. 
IPSC technology continues to be an attractive avenue for basic science to 
achieve clinically relevant applications. Less than a decade after their inception, 
iPSCs are being used as a source of cellular therapeutics (DeGroot and Denison, 
2014) and have undergone successful gene correction in lines created from 
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primary cells of patient populations (Simara, Motl, and Kaufman, 2013). Now, 
there is the potential to turn iPSC-derived cultures into drug screening tools that 
can provide early indices of safety and efficacy before patient populations are 
exposed (Ningzhe Zhang et al., 2016, Rosa et al., 2014, Tzatzalos et al., 2016, 
Xie and Zhang, 2015). Given the widely reported role of AHR signaling in 
hepatotoxicity (Zollner, Wagner, and Trauner, 2010) and carcinogenesis (Safe, 
Lee, and Jin, 2013), our reporter iPSC line is an optimal tool to reveal potential 
toxicity of compounds of interest in pre-clinical phases of development. 
 As the full extent of AHR pathway dynamics are discovered, and the 
mechanisms of endogenous ligand regulation dominate the literature, it will 
become paramount to map AHR activation throughout all phases of 
development. Induced pluripotent stem cells provide an invaluable tool by which 
to derive distinct cellular subtypes of all three germ layers, and the CYP1A1 
reporter line presented in this work can provide an output of AHR activity that can 
be observed in every experimental context. Differentiation strategies that mimic 
in vivo ontogeny have the potential to serve as “temporal maps” of AHR activity 
throughout cytokine driven progression of cells to a distinct lineage. In this work, 
the directed differentiation strategy outlined in Aim 1, Figure 11 was used as part 
of this initiative. Luciferase output confirmed that AHR activity is at its peak when 
the cultures are specified to a MEP-like cell, but that AHR activity is almost 
completely suppressed once these cells are specified to a more defined cell of 
the megakaryocyte lineage (Figure 16A). Interestingly, MPL transcript expression 
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trended upwards as the AHR activation of CYP1A1 was being actively 
suppressed (Figure 16B). This finding further substantiates our model of AHR 
regulation of megakaryopoiesis (Aim 1, Figure 10) and suggests that cytokines 
implicit in megakaryocyte differentiation may have at least an indirect regulatory 
capacity in the modulation of AHR function. Thus, this iPSC line can reveal 
multiple novel roles of AHR signaling as well as the identity and dynamics of 
endogenous ligands that have yet to be discovered.  
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AIM TWO FIGURES 
Aim 2, Figure 1: 12-Phorbol-13-myristate acetate (PMA) induces 
megakaryocyte fate in immortalized megakaryoblasts (Meg01)  
Meg01, the immortalized megakaryoblast line, was plated in an in vitro 
culture in the presence (PMA) and absence (Control) of 40 nM PMA. Flow 
cytometry revealed a shift in the CD41a/CD42b dual positive, megakaryocyte 
lineage restricted immunophenotype as a result of PMA treatment for 3 days. 
Plots are representative of 3 individual experiments. 
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Aim 2, Figure 2: AHR agonism attenuates surface expression of C-MPL on 
Meg01 cells  
  In both uninduced (Naïve Control) and PMA induced (40nM PMA) 
conditions, Meg01 cells displayed surface expression of C-MPL by flow 
cytometry analysis. After PMA induction, 200 nM FICZ was incorporated into the 
media and reduced C-MPL after 3 days of treatment. Plots are representative of 
3 individual experiments. 
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Aim 2, Figure 3: FICZ treated Meg01 cells decrease transcript-level 
expression of MPL 
 As compared to the DMSO control, FICZ treated Meg01 cells (without 
PMA) displayed a significant increase in CYP1B1 transcription and, 
concomitantly, significantly reduced MPL transcript expression. PMA treatment 
increases MPL expression, as expected. When FICZ is added to PMA induced 
Meg01 cells, MPL levels are reduced (as compared to PMA only condition) and 
CYP1B1 is increased. (* P < 0.05.) Error bars represent the SEM of 3 
independent experiments.  
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Aim 2, Figure 4: iPSC derived megakaryocyte progenitors lose C-MPL 
surface expression as a consequence of FICZ treatment 
 iPSC derived hematopoietic cells were subjected to FICZ (AHR agonist) or 
SR1 (AHR antagonist) treatment from Day 12 of differentiation, where they are 
mostly CD41a/CD235a dual positive HPCs, to Day 18, where they are mostly 
CD41a/CD42b dual positive megakaryocyte lineage restricted cells. A) FICZ 
treatment almost entirely attenuates surface expression of C-MPL on CD41+ 
gated cells, whereas SR1 does not affect C-MPL expression (as compared to the 
DMSO control). B) Mean Fluorescence Intensity of three independent 
experiments reveals a significant decrease in C-MPL in the FICZ condition as 
compared to both the DMSO and SR1 conditions. (* P < .005). Error bars 
represent the SEM. 
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Aim 2, Figure 5: Transcription of MPL is suppressed by AHR agonism in 
megakaryocyte lineage-restricted progenitors derived from iPSCs 
 qPCR analysis reveals that FICZ treatment causes increased transcript 
expression of the AHR target gene, CYP1B1, concomitantly with decreased 
expression of MPL, after 5 days in culture (as compared to DMSO control). SR1, 
the AHR antagonist, decreased CYP1B1 expression while causing a relative 
increase in MPL. With both compounds in the same treatment condition, MPL 
levels no longer differed from the DMSO control, implying that FICZ and SR1 
compete to modulate AHR signaling in this context. (* P < .05) Error bars 
represent the SEM of three independent experiments.   
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Aim 2, Figure 6: AHR antagonism causes CD41a+ cells to be retained in 
long-term culture 
 The Day 18 timepoint of the megakaryocyte biased directed differentiation 
protocol produces a large fraction of CD41a+ cells (Aim 1, Figure 12). In this 
experiment, DMSO, FICZ, or another AHR antagonist CH223191 were added 
and maintained in culture for 5 days. At Day 23, further immunophenotyping 
reveals diminishing numbers of CD41a+ cells in the DMSO and FICZ conditions, 
but the cells under 5 days of AHR antagonism with CH223191 treatment retained 
this population. Plots are representative of 3 individual experiments. 
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Aim 2, Figure 7: DGE analysis reveals MPL is among the most differentially 
expressed transcriptional target in the presence of FICZ 
 A) Using the DMSO and FICZ conditions from the experiment outlined in 
Aim 2, Figure 6, digital gene expression (DGE) analysis was conducted to 
analyze the transcriptomic changes that result from AHR agonism. B) MPL was 
among the most differentially expressed gene targets, in this case showing a 
suppression of transcript expression under AHR agonism. (* P < .01). Error bars 
represent the SEM of three independent experiments. 
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Aim 2, Figure 7  
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Aim 2, Figure 8: Transcriptome analysis reveals megakaryocyte-associated 
genes are suppressed by AHR agonism 
 Multiple genes were revealed to be differentially expressed as a 
consequence of FICZ treatment in the experiment outlined in Aim 2, Figure 6. 
Among them are three genes associated with megakaryocyte cell fate and 
platelet function (PF4, SELP, and GP9). All are significantly downregulated as a 
result of FICZ treatment. (* P < .01)  Error bars represent the SEM of three 
independent experiments.  
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Aim 2, Figure 9: Genes associated with heme catabolism and hemoglobin 
variants are upregulated in response to FICZ treatment 
 Erythroid associated genes were significantly upregulated by way of FICZ 
treatment through DGE analysis of the experiment outlined in Aim 2, Figure 6. 
ALAS2 is involved in mitochondrial heme catabolism, and HBA2 is an alpha-
globin gene variant. (* P < .01) Error bars represent the SEM of three 
independent experiments.  
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Aim 2, Figure 9 
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Aim 2, Figure 10: A direct target of TPO cytokine signaling is differentially 
expressed through AHR agonism by way of FICZ treatment 
 Among the top hits in the DGE analysis outline in Aim 2, Figure 6, 
CDKN1A, the gene encoding p21, a cell cycle regulator and direct target of TPO 
signaling, is significantly downregulated as a result of FICZ treatment. (* P < .01). 
Error bars represent the SEM of three independent experiments.  
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Aim 2, Figure 11: Vector design, construction and validation of a CYP1A1 
reporter iPSC line 
A) Two vectors were created to achieve CAS9 targeted digestion at the 
CYP1A1 transcription start site and homologous recombination of a reporter 
construct. The donor plasmid contains a cassette that includes eGFP and 
luciferase separated by an internal ribosome entry sequence (IRES). Directly 
downstream of these reporter elements is a puromycin resistance gene (PURO) 
driven by a constitutive promoter (PGK) and flanked by loxP sites (denoted by 
black arrowheads). This cassette is flanked by regions that are homologous to 
the CYP1A1 endogenous locus (Left Homology, LH; Right Homology, RH) to 
facilitate homologous recombination. The Guide RNA (gRNA) and Cas9 were 
encoded on the same plasmid, each driven by a separate constitutive promoter 
(U6 and CMV, respectively). B) An idealized schematic of Cas9 digestion at the 
transcription start site (denoted by black arrow) of the CYP1A1 locus. C) The 
integrated reporter construct is expected to specifically target the transcription 
start site of CYP1A1, and a PCR strategy was employed that creates amplicons 
in the 5’ and 3’ flanking regions of the cassette that include elements from the 
reporter construct as well as endogenous regions that are not encoded by the 
donor plasmid. D) The 5’ amplicon (expected size = 962 bp) was exclusively 
detected in a properly targeted iPSC clone. E) The 3’ amplicon (expected size = 
704 bp) also could not be amplified in untargeted clones or the parental iPSC 
line, but was detected in a properly targeted iPSC clone.  
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Aim 2, Figure 11
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Aim 2, Figure 12: Sanger sequencing confirms PCR validation strategy of 
CYP1A1 reporter iPSCs  
A) PCR products discussed in Aim 2, Figure 11 were purified and 
sequenced using the Sanger method (Genewiz, Inc). Both amplicons include 
endogenous regions of the CYP1A1 locus as well as elements of the reporter 
construct (eGFP in the 5’ amplicon; puro resistance gene in the 3’ amplicon) B) 
Full sequences for the Left Homology Arm, Right Homology Arm, and single 
guide RNA (sgRNA). 
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Aim 2, Figure 12 
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Aim 2, Figure 13: CYP1A1 reporter iPSCs elicit a response to the AHR 
agonist FICZ  
A) CYP1A1 transcript level expression was increased in both the parental 
cell line (blue bar) and the targeted clone (red bar) in response to escalating 
doses of 6-formylindolo(3,2-b)carbazole (FICZ). B) Luciferase expression was 
observed as a result of FICZ treatment exclusively in the targeted clone (red bar) 
but not in the parental cell line (blue bar), showing that the integrated reporter 
construct was faithfully reporting on AHR-dependent CYP1A1 upregulation. Error 
bars represent the SEM of two independent experiments.  
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Supplemental Figure 2: CYP1A1 reporter iPSCs elicit a response to the AHR agonist FICZ A) CYP1A1 
transcript level expression was increased in both the parental cell line (blue bar) and the targeted clone (red bar) 
in response to escalating doses of 6-formylindolo(3,2-b)carbazole (FICZ). B) Luciferase expression was 
observed as a result of FICZ treatment exclusively in the targeted clone (red bar) but not in the parental cell line 
(blue bar), showing that the integrated reporter construct was faithfully reporting on AHR-dependent CYP1A1 
upregulation.
Parental Line
Targeted Clone
DM
SO
10
e-8
10
e-7
10
e-6
10
e-5
10
e-4
FICZ Concentration (M)
0
2
4
6
B-
Ac
tin
 N
or
m
al
iz
ed
 C
yp
1a
1 
Ex
pr
es
si
on
  
120 
Aim 2, Figure 14: Hepatocyte specification yields luciferase expression in 
cells derived from CYP1A1 reporter iPSCs 
 A) iPSCs were differentiated towards CXCR4+/C-KIT+ definitive 
endoderm (Day 5) followed by FOXA1+/AAT+ hepatic progenitors (Day 14) that 
grew in number and were the majority of the culture by Day 25. B) Micrographs 
show homogenous morphology of definitive endoderm cultures (Day 5), but by 
Day 14, hepatic-like cells begin to emerge (denoted by black arrowheads) and 
are observed more frequently by Day 25. C) Concomitant with hepatic 
specification, luciferase levels significantly increase (N=3, * P <0.0005, Student’s 
t test). Error bars represent the SEM for three independent experiments.  
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Figure 2: Hepatocyte specification yields luciferase expression in cells derived from CYP1A1 reporter 
iPSCs A) iPSCs were differentiated towards CXCR4+/C-KIT+ definitive endoderm (Day 5) followed by 
FOXA1+/AAT+ hepatic progenitors (Day 14) that grew in number and were the majority of the culture by Day 
25. B) Micrographs show homogenous morphology of definitive endoderm cultures (Day 5), but by Day 14, 
hepatic-like cells begin to emerge (denoted by black arrowheads) and are observed more frequently by Day 
25. C) Concomitant with hepatic specification, luciferase levels significantly increase (N=3, *P<0.0005, 
Student t Test)
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Aim 2, Figure 15: Acute exposure to AHR ligands causes a predictable 
response in CYP1A1 reporter iPSCs  
 A) Fibroblast-like cells were differentiated from CYP1A1 reporter iPSCs 
over the course of 2 days using Fibroblast Induction Media. A compendium of 
AHR ligands were then added to the cultures for 24 hours before cells were 
harvested for further analysis. B) Luciferase expression analysis reveals patterns 
of activation and inhibition of the CYP1A1 reporter (Targeted Clone) as a 
response to agonist and antagonist treatment. Significance was established by 
Student’s t Test for each condition compared to the DMSO control condition (*P < 
.01, N=3) Error bars represent the SEM of three independent experiments C) 
Transcript level expression of endogenous CYP1A1 in the Targeted Clone 
showed similar patterns of modulated expression that positively correlated to 
luciferase output. Significance was established by Student’s t Test for each 
condition compared to the DMSO control conditions (*P < 0.02, N=3). Error bars 
represent the SEM of three independent experiments.  
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Figure 3: Acute exposure to AHR ligands causes a predictable response in CYP1A1 reporter iPSCs A) 
Fibroblast-like cells were differentiated from CYP1A1 iPSCs over the course of 2 days using Fibroblast Induction 
Media. A compendium of AHR ligands were then added to the cultures for 24 hours before cells were harvested for 
further analysis. B) Luciferase expression analysis reveals patterns of activation and inhibition of the CYP1A1 
reporter (Targeted Clone) as a response to agonist and antagonist treatment. Significance was established by 
Student’s t Test for each condition compared to the DMSO control condition (*P<0.01, N=3) C) Transcript level 
expression of endogenous CYP1A1 in the Targeted Clone showed similar patterns of modulated expression that 
positively correlated to luciferase output. Significance was established by Student t Test for each condition 
compared to the DMSO control condition (*P<0.02, N=3). 
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Aim 2, Figure 16: Temporal mapping of the AHR throughout hematopoiesis 
 A) Endogenous regulation of AHR was assessed throughout the 
megakaryocyte biased hematopoietic differentiation protocol by measuring 
luciferase output at Days 0, 3, 5, 7, 11, 15, 18, and 20. The Day 11 timepoint was 
the peak of AHR activation, corresponding to the point where the culture is 
predominantly HPCs. (* P < .05, as compared to Day 0; # P < .01, as compared 
to Day 11). Error bars represent the SEM of three independent experiments. B) 
Transcript level expression of MPL was analyzed in parallel to luciferase output 
(shown in A) and displayed a progressive increase in MPL levels starting at Day 
7. (* P < .05, as compared to Day 0; ** P < .01, as compared to Day 0; # P < .01, 
as compared to Day 11). Error bars represent the SEM of three independent 
experiments.  
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AIM THREE 
Our third aim is to identify the role of AHR signaling on late-stage 
megakaryopoiesis and platelet production using an in vivo model of 
megakaryocyte-lineage restricted AHR knockout. 
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AIM THREE METHODS 
Mouse Model  
 Eight week old mice were bought from Jackson Laboratory (Bar Harbor, 
ME). Two strains were purchased; Ahrtm3.1Bra/J (also known as Ahrfx) (JAX 
#006203), and C57BL/6-Tg(Pf4-icre)Q3Rsko/J (also known as Pf4-Cre) (JAX 
#008535). Genotypes were confirmed using the published PCR protocols 
associated with the generation of both mouse strains (Tiedt et al., 2007, Walisser 
et al., 2005). Mice were bred to the F1 generation and littermates with one floxed 
AHR (AHRfl/-) that also had Pf4-Cre transgene expression were crossed to 
produce the desired genotype, AHRfl/fl PF4-Cre+. All studies that used these mice 
used the homozygous AHR floxed mouse without PF4-Cre expression as the 
negative control (AHRfl/fl only). Animals were housed at the Association for 
Assessment and Accreditation of Laboratory Animal Care certified Boston 
University Medical Laboratory Animal Science Center and used in accordance 
with the National Institute of Health’s Guide for the Care and Use of Laboratory 
Animals. A Boston University Medical Campus Institutional Animal Care and Use 
Committee approved the protocol and National Institutes of Health Guide for the 
Care and Use of Laboratory Animals was followed. 
Bone marrow extraction, culture and genotyping 
 Bone marrow was flushed from the femurs of sacrificed mice using a 3 mL 
syringe filled with sterile PBS attached to a 26-gauge needle. The resulting 
aspirate was centrifuged for 5 minutes at 300 x g and the resulting pellet was 
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resuspended in ACK lysis buffer (ThermoFisher #A1049201) and incubated at 
room temperature for 5 minutes. This suspension was then centrifuged for 5 
minutes at 300 x g and the resulting pellet was washed with sterile PBS. This 
washed suspension was centrifuged for 5 minutes at 300 x g and resuspended 
into murine bone marrow meg (MBMM) media I. This culture was left in a 37° C 
incubator for 2 days before the cells were centrifuged for 5 minutes at 300 x g 
and resuspended in MBMM media II. After 2 more days, the cells were 
centrifuged for 5 minutes at 300 x g and resuspended in MBMM media III. These 
media were composed of SP34 with ascorbic acid (50 µg/mL), monothioglycerol 
(4.5-4 M)  primocin (100 µg/mL), and L-glutamine (2mM). Cytokine components 
were the following: MBMM media I, mSCF (50 ng/mL); MBMM media II, mSCF 
(50 ng/mL) and mTPO (50 ng/mL); MBMM media III, mTPO (50 ng/mL). After 24 
hours in MBMM media III, megakaryocytes were fractionated by a Bovine Serum 
Albumin (BSA) gradient, where PBS with 3%, 1.5%, and 0% BSA, respectively, 
were layered on top of each other (2mL per layer) and the cells allowed to pass 
through to the 3% BSA bottom layer by gravity, upon which the densest cells 
(megakaryocytes) would be sufficiently fractionated. The cells were then cultured 
for an additional 24 hours before being imaged by a Celigo imaging cytometer 
(Nexcelom Bioscience) and harvested for gDNA. PCR was performed on both 
fractionated and unfractionated megakaryocyte samples using a multiplex PCR 
strategy previously described (Figure 2) (Walisser et al., 2005). The excised 
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allele gives a 180 bp PCR product while the unexcised allele gives a 140 bp PCR 
product. If present, the wild type allele would give a PCR product of 104 bp.  
TPO ELISA 
 Serum levels of TPO were determined using a commercially available 
ELISA kit (Mouse Thrombopoietin Quantikine ELISA Kit, R and D) and performed 
according to manufacturer’s instructions. Briefly, murine peripheral blood was 
collected and centrifuged for 20 minutes at 2000 x g. Sera was collected and 
diluted in buffer at a 1:5 ratio. It was then added to a pre-treated 96 well plate 
with antibodies raised against TPO.  Relative amounts of TPO were detected by 
a colorimetric reaction and quantified off of a standard curve.   
Flow cytometry 
Platelet Quantification 
 Mouse peripheral blood was suspended in platelet wash buffer (10 mM 
sodium citrate, 150 mM NaCl, pH 6.5) at a 1:10 ratio. An antibody for murine 
CD41a (Ebioscience 25-0411) was then added at a 1:1000 dilution and 
incubated for 20 minutes at room temperature. Calcein AM (ThermoFisher 
#C3100MP) was then added at a 300 nM final concentration and the suspension 
was adjusted to a final volume of 400 µL. 5 µl of a commercially available 
counting bead was then added (Spherotech, #RFP-50-5) allowing for a 
determination of the absolute platelet count, which were defined as CD41a+ and 
Calcein AM + cells. 
Platelet function studies 
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 Mouse peripheral blood was suspended 1:10 in HEPES-Tyrodes Buffer 
(13.7 mM NaCl, 0.27 mM KCl, 0.1 mM MgCl2, 1.2 mM NaHCO3, 0.04 mM 
Na2HPO4, 0.55 mM glucose, and 1 mM HEPES) with BSA supplemented at 0.35 
g/mL and adjusted to a pH of 7.35. Thrombin (Calbiochem #605195) was added 
at a final concentration of 2 U/mL in the presence of an antibody mixture 
including antibodies raised against CD41a (eBiosciences #25-0411), P-Selectin 
(Emfret #M130-1) and GPIIb/IIIa (JON/A) (Emfret #M023-2) added at a final 
dilution of 1:160, 1:2.22, and 1:2.22, respectively. Samples were incubated for 15 
minutes at room temperature and fixed in 1% formaldehyde solution. For GPVI 
expression, the antibody incubation step proceeded without platelet agonist; an 
antibody raised against GPVI (R and D #FAB6758P) was added at a dilution of 
1:100 in the presence of the aforementioned CD41a antibody at a dilution of 
1:160. Samples were incubated for 15 minutes at room temperature and fixed in 
1% formaldehyde solution as described before.    
Histology 
 Bone marrow femurs were fixed in 4% paraformaldehyde (PFA) for three 
days followed by decalcification in 14% EDTA. Decalcified bone marrow was 
then sectioned longitudinally and paraffin embedded and stained with 
hematoxylin and eosin. The decalcification and slide preparation steps were 
performed by the Boston University Experimental Pathology Laboratory Services 
Core. Slides were imaged using a Nikon deconvolution wide-field epifluorescent 
microscope.  
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Multiplate Aggregometry 
 Mouse peripheral blood was analyzed by a multiplate aggregometer 
(Roche) using kits that expose whole blood to platelet agonists and measure the 
electrical resistance between two electrodes as a readout of platelet aggregation. 
150 µl of heparinized blood was added to a cuvette in the presence of 200 µl of 
0.9% NaCl and 12 µl of either ADP (6.4 µM), Collagen (3.2 µg/mL), or a PAR4 
agonist (662 µM). Platelets then began to adhere and aggregate on the electrode 
pair in each test well, and recordings were taken over the course of 5 minutes. 
Final results are displayed as the maximum aggregation in arbitrary aggregation 
units (AU).  
Proplatelet megakaryocyte determination 
 A Celigo imaging cytometer took images of fractionated samples from 
bone marrow cultured megakaryocytes. Images were analyzed by ImageJ 
software, and megakaryocytes were traced and given a score based on the 
extent to which the image trace recapitulated the dimensions of a perfect circle 
(defined as circularity). Proplatelet forming megakaryocytes were defined as 
having a circularity measurement of < 0.25. These events were quantified and 
compared to the total number of events to retain an approximate percentage of 
proplatelet forming megakaryocytes in the culture.    
Statistical analyses 
Results are presented as the mean ± the standard error of the mean.  
Statistical significance was confirmed using the Student’s t-test. 
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AIM THREE RESULTS 
 
The AHR knockout mouse has been shown to exhibit multiple abnormal 
phenotypes associated with a lack of endogenous physiological roles of the AHR 
(Abbott et al., 1999, Baba et al., 2005, Esser, 2009, Fernandez-Salguero et al., 
1995, Garcia-Lara et al., 2015). Among these are the observations that platelet 
counts are reduced and platelet responsiveness to collagen is diminished as a 
result of the loss of VAV1 and VAV3 (Lindsey et al., 2014). To pursue these 
observations further, a mouse model that better reflects the status of AHR 
signaling intrinsic to the megakaryocyte and platelet was created (Figure 1). Mice 
engineered to have LoxP sites flanking exon 2 of the AHR (JAX #006203) 
(Walisser et al., 2005) were bred with a transgenic mouse that expresses Cre 
Recombinase (JAX #008535) (Tiedt et al., 2007) driven by the promoter for 
platelet factor 4 (PF4), a factor that is exclusively expressed in megakaryocytes 
and platelets (Ng et al., 2014). The resulting mouse, known as AHRfl//fl PF4-Cre+, 
produces bone marrow megakaryocytes that are revealed to have successfully 
excised exon 2 of the AHR gene by a previously published multiplex PCR 
strategy (Walisser et al. 2005) (Figure 2B). To isolate megakaryocytes that had 
been differentiated from bone marrow harvested HSCs, a BSA gradient was 
used. PCR of unfractionated samples from the AHRfl/fl PF4-Cre+ mouse 
produced amplicons corresponding to both the unexcised and excised AHR allele 
(Figure 2A), whereas megakaryocytes purified by BSA gradient displayed only 
the amplicon corresponding to the excised allele (Figure 2). This finding confirms 
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the expected genotype of these mice and shows the utility of the transgenic 
system in creating lineage specific knockouts by CRE/LoxP technology. 
Predicated by the observations that AHR signaling affects MPL expression (Aim 
2), and considering the role of MPL expression on circulating platelets in 
endocytosing and degrading serum TPO (Ng et al., 2014), it was hypothesized 
that serum TPO levels may be affected by the loss of the AHR in the 
megakaryocytes of the AHRfl//fl PF4-Cre+ mouse. A commercially available ELISA 
kit was used to assay for relative TPO concentrations and it was found that there 
exists no difference between the AHRfl//fl PF4-Cre+ mouse and the AHRfl/fl only 
control (Figure 3).   
Using flow cytometric analysis in the presence of a known amount of 
counting beads, platelet counts were next determined to test if there was a 
general disruption in megakaryocyte specification and platelet release as a result 
of AHR lineage specific knockout. Indeed, the AHRfl//fl PF4-Cre+ mouse is 
thrombocytopenic relative to the AHRfl/fl only control, suggesting AHR signaling 
that is intrinsic to the megakaryocyte may be required for normal thrombopoiesis 
(Figure 4). To delve deeper into this hypothesis, the bone marrow from AHRfl//fl 
PF4-Cre+ mice was sectioned and imaged in order to assess the megakaryocyte 
compartment, including the presence of high and low ploidy megakaryocytes and 
a suspected decrease in bone marrow megakaryocytes in this mouse model. 
Surprisingly, no differences were seen in any of these parameters between the 
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two conditions, suggesting that megakaryocyte maturation is not impaired in the 
bone marrow despite the observed decrease in platelet production (Figure 5).  
These results caused the focus to shift not to the ability for these mice to 
produce megakaryocytes but for their bone marrow megakaryocytes to extend 
proplatelets. Using cultured megakaryocytes derived from bone marrow HSCs, 
images were taken and analyzed by ImageJ software for relative circularity. Once 
again, despite the observed difference in platelet counts between the AHRfl//fl 
PF4-Cre+ mouse and controls, there was no significant difference in the 
proportion of observed megakaryocytes that could reliably be shown to extend 
proplatelets in culture (Figure 6). Thus, there is no clear phenotype of the 
megakaryocyte compartment that can explain the lowered platelet count of the 
AHRfl/fl PF4-Cre+ mouse.  
In an effort to correlate lowered platelet number to possible defects in 
function, and to follow-up on reports of decreased collagen-dependent 
responsiveness in platelets taken from the AHR-/- mouse (Lindsey et al., 2014), 
GPVI, the dedicated collagen receptor on platelets, was measured by flow 
cytometry. The expression of this receptor was robust in both the AHRfl/fl PF4-
Cre+ and AHRfl/fl only control, and no significant difference exists between their 
expression profiles (Figure 7). Furthermore, multiplate aggregometry was used to 
assess AHRfl//fl PF4-Cre+ platelet response to a PAR4 agonist, Collagen, and 
ADP. None of these experimental paradigms yielded a significant difference 
between the knockout and control mouse conditions, suggesting that platelet 
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defects observed in the whole body knockout may not be entirely due to 
megakaryocyte-intrinsic AHR signaling (Figure 8). Importantly, the lack of defect 
in platelet aggregation in response to collagen is another parameter that can not 
be recapitulated from studies with the whole body knockout (AHR-/-) (Lindsey et 
al., 2014). Further tests were performed to assess platelet agonist 
responsiveness in these mice as a function of thrombin treatment and P-Selectin 
and activated GPIIb/IIIa expression (Figure 9). In this study, no significant 
difference in thrombin induced platelet activation was observed. Therefore, the 
only phenotype from the AHR-/- mouse that can be recapitulated in a 
megakaryocyte-lineage specific knockout is a lowered platelet count, and the 
mechanism for this defect is seemingly idiopathic.   
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AIM THREE DISCUSSION  
The limited abnormal phenotype of the AHRfl//fl PF4-Cre+ mouse provides 
some insight into the ability for megakaryocytes to adapt to the loss of AHR 
signaling in an in vivo context. Key to this work was evidence that suggests the 
AHRfl//fl PF4-Cre+ mouse does not have any other hematopoietic cells that are 
affected by the lack of megakaryocyte-specific loss of AHR signaling (Figure 2). 
As the literature highlights, the AHR-/- mouse is fraught with other pathological 
phenotypes that could affect the megakaryocyte compartment, including defects 
in the vasculature (Lahvis et al., 2000, Nan Zhang, 2011, Thackaberry et al., 
2002, Vasquez et al., 2003) and an impairment of lymphocyte specification 
(Esser, 2009). The observed defect in collagen dependent signaling in the 
platelet compartment of this mouse (Lindsey et al., 2014) was found to be 
caused by a loss of VAV1 and VAV3, two members of a family of guanine 
nucleotide exchange factors (GEFs) that act downstream of collagen binding to 
its dedicated receptor (GPVI) in order to cause activation of phospholipase C  
(Pearce et al., 2004). In the present work, however, there was no observable 
difference in the ability for these platelets to aggregate as a function of a collagen 
stimulus (Figure 8) nor was there a significant decrease in GPVI expression 
(Figure 7). Perhaps, then, this conflicting finding may reveal the utility of the use 
of a conditional knockout (AHRfl//fl PF4-Cre+) rather than a whole body knockout 
(AHR-/-) in order to fully understand the consequences of loss of AHR within the 
megakaryocyte lineage (Eisener-Dorman, Lawrence, and Bolivar, 2008). Indeed, 
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the loss of VAV family GEFs is highly ubiquitous within multiple observed tissue 
types of the AHR-/- mouse (Sauzeau et al., 2010). It is not unreasonable to 
postulate that the downregulation of VAV family proteins observed in platelets of 
the AHR-/- mouse (Lindsey et al., 2014) may not be a megakaryocyte-specific 
affect but rather a relic of the suppression of this factor in earlier hematopoietic 
progenitors, perhaps even in cell types that are upstream of hematopoiesis 
entirely. Studies of the AHR have repeatedly shown instances where the 
consequences of agonism and antagonism are cell type specific; a fitting 
example being the proliferative potential of CD34+ cells in the presence of an 
AHR antagonist (SR1) (Boitano et al., 2010) contrasted to the proliferative 
potential of HPCs in the presence of an AHR agonist (FICZ) highlighted in Aim 1 
of this work. Therefore, the purported lack of a distinguishing phenotype from the 
results outlined in Figures 7 and 8 warrants further discussion and creates an 
opportunity to study AHR dependent modulation of VAV GEFs in a more robust 
way, using multiple model systems and, ideally, in vivo administration of AHR 
modulating compounds.   
 The only observed phenotype within the context of the AHRfl/fl PF4-Cre+ 
mouse that recapitulated observations of the AHR-/- mouse was that of 
decreased circulating platelets (Lindsey et al., 2014) . Previous work has 
attributed this finding to a suspected role of the AHR in regulating megakaryocyte 
ploidy and platelet production (Lindsey and Papoutsakis, 2011) but these defects 
simply could not be recapitulated in the AHRfl/fl PF4-Cre+ mouse. The 
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mechanism of action for decreased platelets can only be left to speculation, but 
may have to do with the ability of bone marrow megakaryocytes to home to the 
bone marrow vascular niche (Kopp, 2005), among other potential hypotheses. 
Further work is needed to acquire a mechanistic understanding of this platelet 
defect.    
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AIM THREE FIGURES 
Aim 3, Figure 1: Breeding strategy for the creation of a megakaryocyte 
lineage specific AHR knockout mouse line 
Mice with loxP sites flanking exon 2 of the AHR (Walisser et al., 2005) 
were bred with transgenic mice that produce Cre Recombinase driven by the 
promoter for Platelet Factor 4 (PF4), a megakaryocyte-lineage restricted factor 
(Tiedt et al., 2007). This led to the creation of AHRfl/fl PF4-Cre+ mice, which are 
presumed to have a bi-allelic excision of exon 2 of the AHR within 
megakaryocytes and platelets.  
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Aim 3, Figure 1  
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Aim 3, Figure 2: Genotyping of bone marrow derived megakaryocytes from 
AHRfl/fl PF4-Cre+ mice 
 Bone marrow aspirates were expanded in culture and fractionated with a 
BSA gradient to isolate and purify megakaryocytes. A multiplex PCR strategy 
was used that is previously described in the literature to detect the unexcised 
AHR allele, resulting in a 140 bp amplicon, or the excised allele, resulting in a 
180 bp amplicon (Walisser et al., 2005). A) Unfractionated samples show both 
amplicons in the AHRfl/fl PF4-Cre+ mice. B) PCR of fractionated megakaryocytes 
of the AHRfl/fl PF4-Cre+ mouse only yields the amplicon associated with the 
excised allele, providing further evidence that AHR excision is megakaryocyte-
lineage restricted.   
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Aim 3, Figure 2  
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Aim 3, Figure 3: Serum TPO concentration is not affected by 
megakaryocyte-lineage AHR knockout 
  Serum TPO was assayed via a commercially available ELISA (R and D) 
and no significant difference between conditions was found. N = 5 for both 
conditions, error bars represent the standard error of the mean. 
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Aim 3, Figure 4: Megakaryocyte-lineage restricted AHR knockout yields a 
significantly lower platelet count  
 Platelets harvested from the peripheral blood of AHRfl/fl PF4-Cre+ mice 
were subjected to flow cytometry with counting beads to determine absolute 
platelet counts. A) Platelets were excluded based upon size (Forward scatter) 
and granularity (Side scatter). B) Platelets were entirely CD41a+ and C) were 
highly positive for the viability stain Calcein AM. D) Platelet counts were found to 
be significantly diminished in the AHRfl/fl PF4-Cre+ mice. (* P< .05). N = 11 for 
the AHRfl/fl PF4-Cre+ condition, N = 9 for the AHRfl/fl only condition. Error bars 
represent the standard error of the mean. 
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Aim 3, Figure 4   
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Aim 3, Figure 5: Bone marrow histology reveals similar numbers of 
megakaryocytes despite megakaryocyte-lineage restricted knockout of the 
AHR 
 Longitudinal sections were taken from mouse femurs of control (AHRfl/fl) 
and AHRfl/fl PF4-Cre+ mice and imaged after hematoxylin and eosin (H and E) 
staining. A) Both high (green arrows) and low (orange arrows) ploidy 
megakaryocytes were observed in both mouse models. B) No difference in the 
total number of megakaryocytes observed in the bone marrow was found. N = 6 
for the AHRfl/fl PF4-Cre+ condition; N = 4 for the AHRfl/fl condition. Error bars 
represent the standard error of the mean. 
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Aim 3, Figure 5  
 
 
 
 
AH
R 
fl/f
l; P
F4
-C
re
AH
R 
fl/f
l
0
2
4
6
8
M
eg
ak
ar
yo
cy
te
s 
pe
r f
ie
ld
A
B
AHR fl/fl; PF4-Cre AHR fl/fl
  
149 
Aim 3, Figure 6: AHR knockout in megakaryocytes is not an impediment on 
proplatelet formation  
 The ability for megakaryocytes from AHRfl/fl PF4-Cre+ mice to produce 
proplatelets was observed in megakaryocytes derived from a 5 day culture of 
harvested bone marrow HSCs. Cultures were imaged and analyzed using the 
circularity parameter in ImageJ software. A) Representative images show both 
spheroid shaped and proplatelet forming megakaryocytes. B) Images are 
analyzed such that each megakaryocyte is traced and relative circularity is 
assessed. C) No significant difference in the proportion of cultured 
megakaryocytes that extended proplatelets was observed. N = 6 for the AHRfl/fl 
PF4-Cre+ condition; N = 4 for the AHRfl/fl condition. Error bars represent the 
standard error of the mean.   
  
150 
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Aim 3, Figure 7: Platelet surface expression of GPVI is unaffected by AHR 
knockout in megakaryocytes 
 A) Representative FACS plots show that platelets derived from both the 
AHRfl/fl PF4-Cre+ mouse and the AHRfl/fl only control robustly express GPVI, the 
receptor for collagen signaling, on the cell surface. B) Quantitative analysis of the 
geometric mean of each histogram plot reveals no significant difference in the 
relative expression of surface GPVI. N = 6 for the AHRfl/fl PF4-Cre+ condition and 
N = 4 for the AHRfl/fl only control. Error bars represent the standard error of the 
mean.  
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Aim 3, Figure 8: Aggregometry studies reveal no difference in platelet 
responsiveness from the peripheral blood of mice with megakaryocyte-
lineage restricted AHR knockout 
 Multiplate aggregometry was used to assay for differences in platelet 
agonist responsiveness of platelets taken from peripheral blood of AHRfl/fl PF4-
Cre+ mice. No differences were observed with respect to A) Collagen, B) ADP, or 
C) PAR 4 agonist treatment. N = 6 for the AHRfl/fl PF4-Cre+ condition; N = 4 for 
the AHRfl/fl condition. Error bars represent the standard error of the mean.   
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Aim 3, Figure 8 
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Aim 3, Figure 9: Megakaryocyte lineage restricted AHR knockout does not 
affect platelet agonist responsiveness 
 Platelets taken from AHRfl/fl PF4-Cre+ and AHRfl/fl only control mice were 
exposed to thrombin and assayed for expression of A) P-Selectin and B) 
activated GPIIb/IIIa. No significant difference was observed in either 
experimental condition. N = 6 for the AHRfl/fl PF4-Cre+ condition; N = 4 for the 
AHRfl/fl condition. Error bars represent the standard error of the mean. 
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Aim 3, Figure 9  
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OVERALL CONCLUSIONS 
 The results presented in this work define a conserved role of the aryl 
hydrocarbon receptor (AHR) in the differentiation of megakaryocytes from 
hematopoietic progenitors. The seminal finding in this work is that cells that 
closely mimic that of the megakaryocyte erythroid progenitor (MEP) exponentially 
expand in culture and overwhelmingly specify to the erythroid lineage in the 
presence of an AHR agonist. This finding led to a series of experiments designed 
to explore the influence of AHR signaling on the ability of hematopoietic 
progenitors to specify to the megakaryocyte lineage. Through observations made 
in CD34+ hematopoietic progenitors (Boitano et al., 2010), it was hypothesized 
that the AHR may negatively regulate thrombopoietin (TPO) by suppressing 
transcription and, as a consequence, surface expression of the TPO receptor, C-
MPL. This revelation made it conceivable that the AHR may regulate a host of 
megakaryocyte and erythroid associated genes, including a direct target of TPO 
signaling.  
These findings add to multiple studies that implicate endogenous roles of 
the AHR in hematopoietic ontogeny (Boitano et al., 2010, Casado, Singh, and 
Gasiewicz, 2010, Casado, Singh, and Gasiewicz, 2011, Mascanfroni et al., 2015, 
Pick et al., 2013, Singh, Casado, et al., 2009). Both of the hematopoietic 
differentiation strategies outlined in this work (Aim 1, Figure 1 and Aim 1, Figure 
11) use what is known from developmental biology to best mimic in vivo 
hematopoiesis (Nakamura et al., 2014, Nostro et al., 2008, Panuganti et al., 
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2013), thus providing a novel system where multiple hematopoietic subsets can 
be studied with respect to AHR signaling. With this in mind, an iPSC line was 
created using CRISPR/CAS9 technology that has a reporter construct integrated 
into the genome directly downstream of the transcription start site of CYP1A1, a 
canonical target of the AHR (Okino and Whitlock, 1995, Shimada et al., 2002, 
Wei et al., 1998). After validating the specificity and fidelity of this reporter cell 
line, it was successfully used to create a temporal map of endogenous AHR 
activity throughout hematopoiesis, culminating in the megakaryocyte 
compartment. This temporal map shows that AHR activity is at its peak in 
hematopoietic progenitor cells (HPCs) that functionally mimic the MEP, but that 
the CYP1A1 signal is drastically downregulated in megakaryocyte lineage-
committed cells. This finding substantiates our previous experiments that 
incorporated small molecule agonists and antagonists, and shows that AHR 
signaling is prone to regulation in iPSC directed differentiation strategies. 
Importantly, it is another line of evidence suggesting that MEPs are unable to 
specify to the megakaryocyte lineage when the AHR is active. 
Finally, a mouse model of megakaryocyte lineage restricted AHR 
knockout was used as an optimized system to study the consequences of a lack 
of intrinsic AHR signaling. Interestingly, the only phenotype that could be 
recapitulated from studies of the AHR knockout mouse (AHR-/-) (Lindsey et al., 
2014, Lindsey and Papoutsakis, 2011) was that of a lowered platelet count. No 
megakaryocyte phenotype was observed, and despite being slightly 
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thrombocytopenic, AHRfl/fl PF4-Cre+ mice had normal platelet agonist 
responsiveness as assessed by multiplate aggregometry. This effectively renders 
a lowered platelet count in this mouse idiopathic, but it also sheds light on the 
fallibility of a whole body knockout mouse model (Eisener-Dorman, Lawrence, 
and Bolivar, 2008). Further studies of the AHR in an in vivo context are crucial to 
address the conflicting findings of these two mouse models. 
Taken together, these results prove that AHR signaling has a defined role 
in megakaryocyte specification. AHR regulation of megakaryocyte and platelet 
production could prove useful in translating iPSC directed differentiation 
strategies to the clinic by making the production of platelets sufficiently scalable 
(Karagiannis and Eto, 2015, Thon et al., 2015). Further, the utility of the reporter 
iPSC line described in this work will make the study of AHR signaling pragmatic 
in multiple developmental contexts. Finally, as more endogenous ligands of the 
AHR are characterized, their efficacy as modulators of erythroid and 
megakaryocyte differentiation will have to be considered (Busbee et al., 2013, 
Phelan et al., 1998, Stejskalova, Dvorak, and Pavek, 2011, Wagner et al., 2016). 
Indeed, modulation of the AHR could prove clinically translational given the 
mounting evidence currently described of its role in the megakaryocyte 
compartment.           
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